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Os copy number variations (CNVs) consistem em segmentos de 
DNA de uma kilobase ou mais, que se encontram num número 
variável de cópias, em comparação com um genoma de referência. 
A deteção de CNVs é convencionalmente realizada através de 
técnicas de citogenética, como fluorescence in situ hybridization e 
array comparative genomic hybridization, ou com base em PCR, 
como multiplex ligation-dependent probe amplification, SNP 
arrays ou deep sequencing. Porém, a evolução da técnica de PCR 
quantitativo em tempo real (qPCR) permitiu que fosse, 
actualmente, considerada o método gold standard para a detecção 
de CNVs devido, sobretudo, ao elevado rendimento, sensibilidade, 
precisão e versatilidade. O presente trabalho descreve o 
desenvolvimento e validação de um método de deteção de CNVs 
através da técnica de qPCR. A metodologia adotada provou ser um 
método preciso e sensível para a detecção de CNVs em regiões 
específicas. 
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Copy number variations (CNVs) consist in DNA segments of one 
kilobase or larger, that are present in variable copy number, in 
comparison to a reference genome. CNVs detection is 
conventionally performed through cytogenetic, such as 
fluorescence in situ hybridization and array comparative genomic 
hybridization, or PCR-based techniques, like multiplex ligation-
dependent probe amplification, SNP arrays or deep sequencing. 
However, the evolution of quantitative PCR (qPCR) allows it to be 
considered the gold standard for CNVs detection, mainly due to its 
high throughput, precision and versatility. The present work 
describes the development and validation of a qPCR method for 
CNVs detection. This method proved to be an accurate and 
sensitive method for CNVs detection in targeted regions. 
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Introduction 
Copy Number Variations 
Copy number variations (CNVs) are defined by Feuk and colleagues as DNA 
segments of one kilobase (1kb) or larger that are present at a variable copy number, in 
comparison to a reference genome
1
. CNVs can be simple in structure, such as gains 
(tandem duplications or insertional transpositions) and losses (deletions), or may involve 
complex rearrangements of the genome, such as gains or losses of homologous sequences 
at multiple sites in the genome
2,3
. Over the years, new variations in the repetitive regions of 
DNA have been identified, suggesting that CNVs might be as important to genomic 
diversity as single nucleotide polymorphisms (SNPs)
4,5
. In fact, CNVs might account for 
about 1% of the inter-individual variation, over the 0,1% accounted for SNPs
6
. 
The HapMap Project revealed that regions with copy number variation cover 
approximately 12% of the human genome, and other studies found out that approximately 
one-third of them are unique to the human species. Regarding evolution, through multiple 
generations, deletions are usually selected against, while duplications may experience 
positive selection, as suggested by the existence of gene families
4
. Large CNVs usually 
exist due to de novo events, since they typically suffer negative selection
5
. CNVs <1kb in 
size are of particular importance to genetic medicine, since they are more numerous than 
the larger CNVs
7
. Also, CNVs generally are located outside of coding sequences and ultra-
conserved regulatory elements, which are sequences of at least 200bp that are 100% 
conserved across several species
2
. CNVs can involve one or multiple genes, being 
presented as a recessive or dominant allele, due to variations in gene expression through 
gene dosage effects. Also, gene expression can be altered through position effects due to 
the disruption of the coding region or deletions or duplications outside the coding 
sequences
2,7
.  
Regarding functional categories, genes involved in cell adhesion, the sensory 
perception of smell, neurophysiological  processes, brain development, and responses to 
chemical stimuli, such as immune responses and drug metabolism, are the most enriched in 
CNVs
4,7
. On the other hand, genes involved in cell signalling and cell proliferation, as well 
as in regulation of protein phosphorylation are the less represented
4
. While some CNVs 
have no apparent influence on phenotype, others have been implicated in the aetiology of 
2 
monogenetic and complex disorders
4,7
. Also, their interaction with additional genetic or 
environmental factors may influence detection of their phenotypic effect 
4
.  
Routine screening in clinical diagnostics passes by the measurement and analysis of 
CNVs, which can assist in subsequent prognostic monitoring. The currently used 
techniques applied in CNV studies are fluorescence in situ hybridization (FISH), 
comparative genome hybridisation (CGH), single nucleotide polymorphism (SNP) arrays, 
deep sequencing, multiplex ligation-dependent probe amplification (MLPA), and real-time 
quantitative PCR (qPCR)
8,9
. 
 
Fluorescence in situ Hybridization 
Fluorescence in situ Hybridization (FISH), is a molecular cytogenetic technique 
that allows direct examination of chromosomal DNA molecules and the visualization of 
specific sequences in the nucleus and/or on metaphase chromosomes
7,10
. FISH uses 
fluorescently labelled DNA probes that are hybridized to metaphase chromosome spreads 
or interphase nuclei, immobilized on a glass slide
7,10
. Thus, it allows to locate the physical 
position of specific DNA sequences that hybridize to the probes on the chromosomes, 
through examining of the preparation with a microscope
10,11
.  
There are several FISH-based techniques that can be performed, depending on the 
application. The visualization and analysis of genetic changes affecting one or a few 
specific genes or loci in individual interphase nuclei can be performed through FISH
12
. 
Fiber-FISH has the highest resolution, ranging from 5 to 500kb, being the preferred 
method to precisely determine the genomic structure of complex CNVs
7
. Also, FISH can 
be performed with multiple labelled probes with different fluorochromes, being widely 
used in clinical diagnosis in order to confirm the presence of CNVs, for example
7,10
.  
However, FISH has several limitations. FISH analysis requires the availability of 
the specific probe for the gene or locus of interest, with the appropriate size and location 
and so, it cannot be used to screen unknown genetic aberrations
12
. Additionally, locus-
specific probes are expensive and the procedure is time-consuming and labour intensive
7
. 
Also, smaller copy number changes (less than 10kb) are too small to be detected by FISH, 
requiring other molecular methods
12
. Moreover, only a limited number of chromosomal 
loci can be screened in a single experiment
7
. 
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Comparative Genomic Hybridization and Array Comparative Genomic 
Hybridization 
Comparative genomic hybridization is a cytogenetic molecular technique, 
introduced around the 1990s, that allows genome-wide screening for CNVs
6,13
. It provides 
alternative means for cytogenetic analysis such as banding patterns (G-banded 
karyotyping) and FISH. In CGH, a test and a control genome are differentially labelled and 
competitively hybridized to metaphase chromosomes. The fluorescent signal intensity of 
the labelled test DNA relative to that of the reference DNA can be linearly plotted across 
each chromosome, allowing for the identification of copy number changes. CGH can be 
used to quickly scan an entire genome for imbalances, and does not require cells that are 
undergoing division. However, the resolution of the CGH has been limited to alterations of 
approximately 5-10Mb for most clinical applications
14
. 
Array CGH (aCGH) combines the principles of CGH with the use of microarrays, 
in order to overcome some limitations of conventional CGH. It uses slides arrayed with 
small segments of DNA as the targets for analysis, instead of metaphasic chromosomes, 
allowing to test a smaller sample size
14,15
. These microarrays are created by the 
immobilization of small amounts of DNA (probes) on a solid support, in an ordered 
manner
14
. Probes vary in size, from large genomic clones, such as the earlier bacterial 
artificial chromosomes (BAC), to synthetized oligonucleotides
6
. The BAC-based arrays 
allow the detection of single-copy losses or gains, usually being targeted to subtelomeric 
and pericentromeric regions and areas within the genome known to be associated with 
diseases, such as microdeletion and microduplication syndromes
6,16,17
. The more frequently 
used though are oligonucleotide aCGH, which allows genome-wide interrogation and more 
precise identification of breakpoints, providing high accuracy and reproducibility
6,18
. The 
oligonucleotides represent areas of interest, being more flexible in terms of probe selection 
and facilitating high probe density and customization of array content
14,16
. Arrays designed 
specifically for copy number analysis use longer oligonucleotide probes (~60-mer), that 
provide a better signal-to-noise ratio than the shorter oligonucleotide probes (~22-mer) 
used in some SNP-detecting array platforms
17
. The resolution of aCGH (up to 1kb) is 
4 
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Figure 1 – Overview of the reference design for array 
comparative genomic hybridization. 
The extracted test and reference DNA are labelled 
with different fluorescent dyes and mixed together in 
equal proportions. Then, they are applied to a 
microarray and both DNAs compete to hybridize 
with the array probes. The relative fluorescence 
intensities are captured and quantified by digital 
systems and the fluorescence ratio between the two 
signals is determined at different positions along the 
genome. Adapted from Szuhai, K. & Vermeer, M. 
Microarray Techniques to Analyze Copy-Number 
Alterations in Genomic DNA: Array Comparative 
Genomic Hybridization and Single-Nucleotide 
Polymorphism Array. J. Invest. Dermatol. 135, 1–5 
(2015). 
higher than that of conventional CGH and is determined by considering both probe size 
and the genomic distance between DNA probes (probe density)
14,15
.  
The basic methodology for aCGH 
analysis is independent of the probe 
type
14
. The experimental design will 
depend on the objective of the study, as 
well as on the sources of variability
19
. 
Most studies apply the reference design 
(Figure 1), where initially, DNA is 
extracted from a test sample, followed by 
the labelling with a fluorescent dye of a 
specific colour
14,19
. On the other hand, 
DNA extracted from a normal control 
sample, usually from several healthy 
donors, is labelled with a dye of a 
different colour
14,18
. Both DNAs are then 
mixed together in equal proportions and 
applied to a microarray
15
. The single-
stranded denatured DNA from both the 
sample and control competes to hybridize 
with the array single-stranded probes, 
and any unbound DNA is stringently 
removed by washing
14,18
. However, this 
design uses half of the available 
resources to analyse a reference sample 
that is not of biological interest, not being 
cost effective. Alternatively, the dye-
swap design, that also needs an on-chip 
reference sample, reduces artifacts due to 
the probe-specific dye biases. In the dye-
swap design, each sample is run in duplicate, with one of the replicates labelled with the 
Cy3 dye and the other on a separate array with the Cy5 dye. Nevertheless, this requires the 
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doubling of every sample hybridization, increasing the cost of the study in comparison to 
the reference design. Another set of design does not require on-chip reference samples, 
since off-chip references can be utilized. The use of an off-chip reference processed on the 
same day possesses similar precision in copy-number estimates as an on-chip reference. In 
a balanced-block design, two groups of interest can appear on each assay simultaneously. 
If there are more than two groups of interest, not every group can appear at the same time 
on each array, resulting in a balanced incomplete-block design. Although balanced-block 
and incomplete-block designs still require that each group is half labelled with Cy3 
fluorescent dye and the other half labelled with Cy5 fluorescent dye, they are more 
efficient than a reference design. Also, these designs allow investigators to nearly double 
their sample size while using the same number of arrays as required for a reference design. 
This increases the statistical power, which is very important in genome-wide research 
studies exploring the association between copy number and disease
19
. Regardless of the 
previously chosen design, the relative fluorescence intensities of the labelled DNA probes 
that have hybridized to each target are captured and quantified by digital imaging systems. 
The fluorescence ratio of the test and reference hybridization signals is determined at 
different positions along the genome. This provides information on the relative copy 
number of sequences in the test genome as compared to the normal genome
14,15
.  
The main advantage of aCGH is its capacity to simultaneously detect aneuploidies, 
deletions, duplications, and/or amplifications of any locus represented on an array, also 
being less labour-intense and expense-saving, with a faster turnaround time
14,15
. The 
application of aCGH on the high resolution measurement of gains and losses of DNA 
sequence was developed by Pinkel and colleagues
7,20
. Since then, multiple whole genome 
CNVs studies in normal populations have emerged, now being a commonly ordered 
clinical genetic test
16,17
. It is a powerful tool for the detection of sub-microscopic 
chromosomal abnormalities in individuals with idiopathic intellectual disability and 
various birth defects
14
. The sensitivity of aCGH is determined by the number and density 
of the probes and their resolution, and it must accurately detect imbalances smaller than 
5Mb in order to be advantageous over G-band karyotyping
16
. Also, an international 
consensus statement recommended aCGH as a first-line genetic test, instead of 
conventional karyotype analysis, for patient with unexplained developmental 
delay/intellectual disability, autism spectrum disorders, and multiple congenital 
6 
anomalies
17,21
. The use of oligo arrays have improved aCGH resolution, which allows 
better detection and mapping of localized changes, such as microdeletions and 
microduplications
16,22
. Moreover, aCGH testing can be subjected to automation, high-
throughput objective analysis and quality control
15,16
.  
However, aCGH can only potentially detect “unbalanced chromosomal changes”, 
failing to detect balanced genomic rearrangements, such as translocations or inversions, 
since the amount of DNA within the sample does not differ from the control DNA, as well 
as low-level mosaicism
15–17
. Also, polyploidies are not detected because there is no loss or 
gain of DNA content at a scale smaller than the chromosome
15
. In addition, the 
identification of novel variants of unknown significance (VOUS) through aCGH may 
cause difficulties in clinical management, since they cannot be clearly classified as benign 
or pathogenic
15,16
. Therefore, the development of CNVs databases, such as the 
International Standards for Cytogenomic Array (ISCA) Consortium from within the 
Database of Genotype and Phenotype (dbGaP) at the National Center for Biotechnology 
Information and the Database of Genomic Variants (DGV) facilitates the resolution of 
VOUS into benign or pathogenic variants
16,17
. The key to overcome this disadvantage is to 
increase sensitivity and specificity, through the selection of a microarray that is capable of 
detecting the majority of pathological CNVs without detecting too many VOUS
16
. Up to 
date, aCGH is more expensive than conventional cytogenetic testing, since higher probe 
density increases the cost per analysed sample
15,18
. 
 
Single Nucleotide Polymorphism Arrays 
Single Nucleotide Polymorphism (SNP) Arrays are widely used for genome-wide 
association studies (GWAS), which contributed greatly for population genetics and genetic 
epidemiology
23
. Nevertheless, the widespread availability of SNP array data contributed to 
its application in CNV discovery and mapping
7,23
. Nowadays, commercial SNP arrays 
offer high genomic coverage, at somewhat affordable prices and improvements in genomic 
regions previously problematic
23
. 
SNP arrays are based on hybridizations with SNP marker probes designed 
specifically for particular genomic locations, typically targeting biallelic SNPs. For each 
SNP, an array platform includes two types of hybridization probes specific to two types of 
7 
known alleles. Thus, the SNP genotype can be determined by the ratios of the 
hybridization intensities for each probe, which can be altered due to CNVs. Computational 
methods use hybridization intensities and allele frequencies from SNP markers, in order to 
detect common or rare CNVs
24
. 
The main limitations of SNP arrays are that they are still relatively expensive and 
not ideal when thousands of samples need to be screened. Moreover, the power of SNP 
arrays is limited by their resolution by a lower detection limit of ~10–25 kb7. 
 
Deep Sequencing 
Next-generation sequencing technologies (NGS) are based on various 
implementations of cyclic-array sequencing, redefining the study of CNVs. NGS platforms 
allow for the sequencing of millions of short DNA fragments simultaneously and may 
process a whole human genome in a relatively short period of time and at a reasonable 
price
25
.  
Nowadays, rapidly developing NGS technologies provide a sensitive and accurate 
alternative approach for accessing genomic variations
26
. Short reads from NGS platforms 
are randomly sampled from the entire genome, as opposed to array-based approaches, 
where probes are predefined for limited genomic regions. The NGS approach also has the 
advantages of possessing a higher coverage and resolution, more accurate estimation of 
copy numbers, more precise detection of breakpoints, and higher capability to identify 
novel CNVs
27
. However, the use of NGS for CNV identification has been limited by a lack 
of available and effective statistical approaches
26
. 
 
Multiplex Ligation-dependent Probe Amplification 
Multiplex ligation-dependent probe amplification (MLPA) was first described in 
2002 by Schouten and colleagues and developed for the detection of large mutations in 
disease-related genes
28,29
. It is a PCR-based technique that has been applied to the 
investigation of a wide variety of genetic disorders, expression analysis, methylation 
identification, multi-colour labelling as well as stuffer-free and multiple-oligo probe 
design
29,30
. MLPA is used for the large-scale screening of samples for the presence of copy 
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number variations at the genomic level (gains or losses) in a test DNA, compared to a 
control
31,32
. Several studies have demonstrated that MLPA allows sensitive and accurate 
detection of disease-specific clinically significant copy number changes
30
. Furthermore, 
two variations of MLPA have been developed for mRNA profiling (RT-MLPA) and 
methylation profiling (MS-MLPA)
33
.  
In MLPA, probe pairs are designed against genomic regions of interest (test 
probes), along with another set of probes that serve as reference probes, being able to 
utilize up to 45 specific probes for different DNA sequences
32,34
. Each MLPA probe 
(Figure 2) consists of two oligonucleotide half-probes, with target-specific sequences, that 
anneal to adjacent sites on DNA, and a generic primer pair attached to the upstream half-
probe (also known as short probe and/or left probe oligonucleotide, LPO) at its 5’ end and 
to the downstream half-probe (also known as right probe oligonucleotide, RPO) at its 3’ 
end
32–34
. Moreover, one or both half-probes contain a stuffer sequence, which allows the 
differentiation of the reference and test probes length during electrophoresis, and, 
therefore, the size of the amplification product
32,34
. The complementary regions of the 
MLPA probes range from 19 to 43 nucleotides in length, and the stuffer sequence ranges 
from 19 to 370 nucleotides, creating a final ligated probe sequence ranging from 130 to 
480 nucleotides, which are separated in size by 6 to 9 nucleotides
33
. The reference probes, 
used for normalization of the amount of PCR products from different reactions, hybridize 
to copy-number stable regions that are not subjected to variations, such as SNPs or 
structural variations
29,32
. 
The MLPA reaction (Figure 2) begins with denaturation of genomic DNA, at 98ºC 
for 5min, followed by incubation with a mixture of probes that hybridize to single-stranded 
DNA, at 60ºC for 16 to 20 hours, to allow complete hybridization. Then, only if the two 
half-probes hybridize to contiguous sequences, without a single gap, they are joined 
together by NAD-dependent DNA ligase, i.e., the ligation reaction occurs, at 54ºC
32–34
. 
The following dosage-dependent PCR amplification is carried out using only one pair of 
primers, complementary to generic sequences, whose 5’ ends are fluorescently 
labelled
32,34
. Thus, PCR does not amplify the target sequences, but the ligated probes
34
. 
Therefore, using the same PCR primers, with equal efficiency, different target sequences 
can be amplified, mitigating amplification issues due to different primer efficiencies
33
. 
Afterwards, PCR products are separated by size and detected through capillary 
9 
electrophoresis
29,32
. Each specific probe migrates according to its molecular weight and the 
resulting electropherograms show PCR-derived-fluorescence-specific peaks that 
5’ Primer site 3’ Primer site 
Stuffer sequence RPO 
LPO 
Ligation 
PCR Amplification 
Denaturation 
DNA 
Hybridization 
Target A Target B 
Capillary Electrophoresis 
and Data Analysis 
Figure 2 – Schematic representation of the multiplex ligation-dependent probe 
amplification process. 
The MLPA reaction begins with the denaturation of the DNA, followed by the immediate 
incubation with the MLPA probes, in order to occur hybridization. Then, the ligation 
reaction occurs, joining the two half-probes. The subsequent PCR reaction occurs using 
only PCR primers pairs, amplifying the MLPA probes. Afterwards, the PCR products are 
separated by size and detected by capillary electrophoresis, followed by normalization 
and data analysis. Adapted from Willis, A. S., Veyver, I. Van Den & Eng, C. M. 
Multiplex ligation-dependent probe amplification (MLPA) and prenatal diagnosis. 
Prenat. Diagn. 32, 315–320 (2012). 
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correspond to each probe
31
. The intensities (height or area) of the peaks are measured, 
quantifying the amount of PCR product, followed by normalization and comparison to 
control DNA samples
31,34
. This indicates the relative amount of target DNA sequence in 
the input DNA sample, with peak ratios between 0,7 and 1,3 considered normal, ratios 
above 1,3 or below 0,7 indicating the presence of a gain or a loss of the target sequence, 
respectively
33,34
.  
The interpretation of the MLPA results is a key step in the application of this 
methodology for molecular diagnosis of deletions and/or duplications. Results 
interpretation can be challenging due to different PCR efficiencies among the different 
probes and sample-to-sample variations. Different strategies for data analysis, such as 
Coffalyser, have been developed to allow correct interpretation of raw data
34
. 
The main advantages of MLPA are its low cost, reliability, high-throughput and 
speed, since it can be completed within 24 to 48 hours. Besides, it is relatively simple to 
implement, requiring minimal training for an experienced technician
31,33
. Moreover, 
MLPA can detect small changes, at the level of a single exon. Comparing to another 
methods, MLPA requires less DNA, is less technically demanding, is faster than Southern 
blotting,  and yields fewer results of unclear clinical significance than quantitative PCR
33
.  
However, like any dosage technique, MLPA is sensitive to DNA quality, being 
sensitive to contaminants and DNA degradation, and requiring 100-200ng of DNA for 
reliable and reproducible results. Furthermore, MLPA is sensitive to the kind of sample 
that is used for DNA extraction
34
. It is recommended to compare different MLPA analysis 
only if they come from the same DNA extraction method, from the same tissue, with 
control DNA ideally from the same type of source material, and extracted in the same 
manner as the test sample, in order to reduce variability
33,34
. MLPA cannot detect copy 
neutral loss of heterozygosity and may experience problems with mosaicism, tumour 
heterogeneity, or contamination with normal cells
34
. The DNA ligase used in the ligation 
step is sensitive to the presence of mismatches near the ligation site, however, mismatches 
further away from the ligation site may have little to no effect on the ligation
33
. If a 
pathogenic point mutation or polymorphism not affecting gene function occurs within an 
MLPA probe-binding site, it might hamper the correct hybridization of the probe, resulting 
in failure of ligation that will appear as a deletion of a whole exon
34
. Sometimes, due to 
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Denaturation (95ºC) 
and 
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Repeat for n cycles 
Extension (72-74ºC) 
Figure 3 – The basic steps in the polymerase 
chain reaction. 
PCR consists in the repetition of the cycle that 
comprises three main phases: denaturation of the 
dsDNA at high temperatures; annealing of the 
primers to their complementary sequence in the 
DNA template; and extension of the chains 
through DNA polymerase synthesis activity. 
Adapted from Griffiths AJF. Introduction to 
Genetic Analysis. 10th ed. Winslow S, editor. W. 
H. Freeman & Company; 2012. 
sequence constraints within the exon, probes may target nearby intronic sequences and 
signal changes observed for these probes may not reflect the copy number of the exon 
itself
33
. Therefore, an independent method must be applied to verify apparent single exon 
deletions detected by MLPA
34
.  
 
Polymerase Chain Reaction 
The polymerase chain reaction (PCR) technique was developed in 1983, by Kary 
Mullis, awarded with the Nobel Prize in Chemistry in 1993
35
. PCR is based on the 
principle that, through a set of reagents, one can exponentially amplify a chosen region of a 
DNA molecule in vitro, mimicking the naturally occurring cellular process
36,37
. This 
mixture of reagents includes a template DNA, multiple copies of a pair of synthetized 
primers, a heat-tolerant DNA polymerase and a supply of nucleotides
37
. The chosen 
primers determine the region to be amplified. The most widely used DNA polymerase is 
Taq DNA Polymerase I, from the bacteria Thermus aquaticus, that is naturally occurring of 
thermal vents and hot springs. This enzyme 
is thermostable and can resist to high 
temperatures, where DNA polymerases from 
other species would denature
10,37
.  
The PCR comprises a sequence of 
steps that occur in a thermal cycler at 
different temperatures (Figure 3). It initiates 
with the denaturation of the template DNA 
at high temperature, usually around 95ºC. 
The hydrogen bonds that bind the two 
strands of the double-stranded DNA break 
and single-stranded DNA molecules are 
formed
10,37
. This step is followed by the 
annealing, i.e. the hybridization, of the 
oligonucleotide primers to their 
complementary sequences in the DNA 
template, at a lower temperature, around 50 
12 
to 60ºC. Each one of the primers binds to a different end of the gene or region to be 
amplified, in opposite DNA strands with their 3’ ends pointing at each other37. At this 
temperature, the single stranded DNA could be re-joined, but the excess of the primers, 
that anneal specifically to each strand, prevents this
10
. The temperature is raised until the 
optimal temperature of the Taq polymerase in use, around 72-74ºC
37
. The Taq polymerase 
binds to the ends of the primers, allowing  for synthesis of the complementary new DNA 
strands from the primer, the extension phase
10,37
. At this point, the generated molecules 
have identical 5’ ends, but different 3’ ends, due to the randomness of the DNA synthesis 
finish, forming the “long products”10. Then, this cycle repeats itself many times, 
exponentially increasing the number of DNA molecules, denaturing the “long products” 
and forming “short products”, where the 5’ and 3’ ends are defined by the primers 
annealing positions. These “short products” are identical to each other and ideally double 
at each cycle, while the reagents are being depleted.  
 
1) Real-time Quantitative PCR 
The number of DNA molecules present in the starting mixture directly affects the 
quantity of product synthetized in a given number of PCR cycles. Eventually, the 
exponential rate of amplification of the PCR reaction stops due to inhibitors of the 
polymerase reaction in the template, reagent limitation or accumulation of pyrophosphate 
molecules, generating variable amounts of PCR product. At this point the quantitation is 
not reliable, therefore the extrapolation should be made at the exponential phase of the 
reaction
35,38
. Initially, these comparisons were made through agarose gel electrophoresis 
that, although simple and easy to perform, is imprecise. Nowadays, the quantitation is 
carried out by real-time quantitative PCR (qPCR), that allows the measurement of the 
product synthesis over time, during the PCR cycles
35
.  
In 1993, the first publication describing qPCR was published
35
. Quantitative PCR 
was developed for DNA quantitation, allowing specific and sensitive quantitation of 
nucleic acids
39,40
. It is advantageous over other methods of gene expression analysis, since: 
(a) it does not require post-PCR manipulation, reducing contamination risk; (b) it has low 
instrumentation and consumable costs, a fast turnaround and assay development time, and 
an open format; and (c) it is highly sensitive, requiring minimal amounts of input DNA
41,42
. 
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Figure 4 – Model of a single amplification plot 
illustrating the nomenclature commonly used in 
qPCR. 
The PCR goes through three phases, the 
exponential, the linear and the plateau phases. The 
PCR product increases throughout the cycles, 
increasing the fluorescence emission and 
generating a sigmoidal curve. Adapted from Arya, 
M., Shergill, I. S., Williamson, M. & Gommersall, 
L. Basic principles of real-time quantitative PCR. 
Expert Rev Mol Diagn 5, 209–219 (2005). 
It is widely used in biomedical research and diagnosis, particularly in mRNA expression 
studies, DNA copy number measurements in genomic or viral DNAs, allelic discrimination 
assays, expression analysis of specific splice gene variants, as well as other scientific 
fields, such as water, food and feed testing
38,40
. Furthermore, qPCR has been used to 
validate aCGH results, such as the ones regarding CNVs, in several studies
22,43–46
.  
During qPCR, the thermocycler 
collects fluorescence emission data that are 
analysed by the computer software, which 
constructs amplification plots, in the form 
of a sigmoidal amplification curve (Figure 
4)
38,41
. When analysing these plots, it is 
important to recognize some important 
nomenclature related to PCR. First of all, 
the baseline is the PCR cycles where the 
fluorescence signal remains beneath the 
limits of detection of the thermocycler, 
usually until cycle 15. The software 
calculates the threshold based on the 
standard-deviation of the average signal of 
the baseline signal, although it can be 
manually altered. It is considered a real 
signal when a fluorescent signal is above 
the threshold, and it can be used to define the threshold cycle (Ct) for a sample
38,42
. The Ct, 
or the quantification cycle (Cq), is the fractional cycle at which the reporter fluorescence is 
higher than the threshold, being essential for accuracy and reproducibility. It is inversely 
proportional to the initial amount of input DNA, and it always occurs during the 
exponential phase of the amplification, in the early cycles of the reaction. As the PCR 
continues, the amplification rate decreases until it reaches the plateau phase, where the 
fluorescence stabilizes
38,41
.  
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2) Experimental Design 
Although it might seem a simple technique, the PCR experiment design must be 
well thought and planned, with all the assays run under the same conditions
47
. All the steps 
can limit efficiency, sensitivity and accuracy of the technique. In qPCR the aim is to 
minimize the interference with the doubling of the target amplicon at each cycle, in order 
to maximize efficiency
39
. PCR efficiency, often expressed in percentage (%), is defined by 
Bar and colleagues as “the fraction of double-stranded DNA molecules that is copied at a 
given cycle”, with an efficiency of 100% representing a perfect doubling of all DNA 
molecules
40
. PCR efficiency is often affected by MgCl2, primer and probe concentrations
47
. 
qPCR assays must be appropriately designed in order to amplify target DNA with at least 
90% efficiency
48
.  
The optimization of the amplification step is essential and can be achieved through 
modifications of the nucleic acids preparation protocol and the choice of adequate primers, 
buffers and cycling conditions
39
. The nucleic acids purity of samples, frequently obtained 
from fixed archival, fresh cell culture or blood products, is highly important in order to 
have reproducibility. In order to determine DNA purity and the presence of PCR inhibitors, 
if possible, each DNA sample should be tested with a standard curve
47
.  
The primers design is of extreme importance for the success of a PCR, because 
incorrect primers can result in no amplification at all or in non-specific amplification of 
multiple fragments. The primers sequence must flank and be complementary to the target 
region on the DNA template, with their 3’ ends pointing towards one another. The size of 
the primer is also of great importance to achieve specific hybridization. On one hand, a 
primer that is too short might hybridize to non-target sites and produce undesired 
fragments. On the other hand, a long primer hybridizes at a slow rate, and complete 
hybridization does not occur in adequate time, reducing the efficiency of the PCR. Thus, 
primer’s optimal length is between 15 and 20 nucleotides, with a GC content of 20-80%, 
and the melting temperature (Tm) for both primers of the pair should be similar (ΔTm ≤ 
2ºC). In order to maximize the specificity of primers, it is recommended for each primer to 
have only one or two Gs or Cs within the last 5 nucleotides, at the 3’ end. The generated 
DNA fragment, the amplicon, ideally should be less than 1kb in length, in order to 
maintain the amplification efficiency, obtain consistent results and be tolerant to reaction 
conditions. When the utilization of probes is required, probe design also follows a set of 
15 
specifications. In order to guarantee that the probe is fully hybridized during primer 
extension, it is desirable that the probe Tm is 8-10ºC higher than the Tm of the primer
10,38
.  
Regarding to the temperature conditions, the annealing temperature (Ta) is the most 
important, once it can affect the specificity of the reaction. At high temperatures, the 
hybridization cannot occur, and the primers and template DNA remain dissociated. In 
contrast, at low temperatures mismatched hybrids are frequent and stable, producing non-
target amplification. Hence, the annealing temperature must be low enough to allow 
hybridization, but high enough to prevent the formation of mismatched hybrids. In order to 
estimate this “perfect” temperature, one should calculate the Tm of the primer-template 
hybrid, at which they dissociate, that is 1-2ºC higher than the annealing temperature. 
Therefore, the primers should have identical Tm so the annealing temperature is adequate 
for both. The Tm can be determined experimentally or, more frequently, it can be 
calculated from the formula: 
Tm (ºC) = 4 x (G + C) + 2 x (A + T) 
in which (G + C) is the number of G and C nucleotides in the primer sequence, and 
(A + T) is the number of A and T nucleotides
10
. The hot start consists of starting the PCR 
reaction at high temperature, in order to eliminate unwanted hybridization that is frequent 
in the first cycle. This increases sensitivity and reproducibility of the amplification and 
quantitation
39
.  
As previously described, quantitation should be performed in the exponential phase 
of the PCR, frequently somewhere between the 15
th
 and the 30
th
 cycles. These are usually 
associated with the linear range of amplification, where the quantitated amount of 
amplified target is proportional to the initial amount of target molecules. Often, this linear 
range of amplification is defined through the testing of control samples or standards
39
.  
 
3) Normalization and Reference Genes 
During qPCR experiments, specific errors are introduced due to minor differences 
in the starting amount, the quality of DNA, or the PCR amplification efficiency. In order to 
minimize these errors and correct non-specific variation, data from qPCR should be 
submitted to appropriate normalization. Usually, reference genes in CNVs studies, or 
16 
housekeeping genes in the case of expression studies, are selected in the surrounding area 
or on the same chromosome as the disease gene
42
. While a housekeeping gene should be 
theoretically expressed at a constant level in different tissues of an organism, at all stages 
of development, and in different experimental conditions, the reference gene should not 
have CNVs described in the literature. Generally, the housekeeping genes are 
indispensable for the cellular regular function. These internal reference or housekeeping 
and the target gene are then simultaneously amplified, with the assumptions that their copy 
number is equal or their expression is similar between all samples and resistant to 
experimental conditions, since it undergoes all steps of the qPCR with the same kinetics as 
the target gene
35,38
. The choice of the reference gene must be made with regard to the 
specificities of each experiment, since it significantly influences the results reliability. 
However, there has not been identified an unequivocal reference gene yet and the use of 
several simultaneous reference genes has been suggested, with their mean quantitation 
used for normalization
38
. This approach is useful when the housekeeping gene is affected 
by the experimental design and treatments or when comparing different tissue types and 
provides a more robust, reliable and accurate quantitation
35,42
. Some of the commonly used 
reference genes include β-actin, GAPDH35,38,49,50, ZNF8041,51–55 or GPR1541,52,54. 
 
4) Amplicon Detection 
During the qPCR experiment, the product accumulation may be followed by one of 
several different chemistries, including double stranded DNA specific binding dyes, i.e. 
dsDNA-intercalating agents, or fluorescent probes, such as hydrolysis probes, dual 
hybridization probes and molecular beacons
38,41
. It is important to select the adequate 
method for a specific PCR assay, according to its objective. 
The dsDNA-intercalating agents are nonsequence-specific fluorogenic DNA-
binding dyes that intercalates into dsDNA. It is the simplest method, relatively cheap, and 
includes SYBR
®
 Green I and EvaGreen
®
. When bounded to double-stranded DNA, the dye 
gives a fluorescent signal, measuring the total amount of double-stranded DNA at the end 
of the elongation step of each PCR cycle. However, it might overestimate the true amount 
of product because it binds to all dsDNA, such as non-specific PCR products and primer-
dimers that sometimes are formed. In order to increase the reaction specificity, melting 
17 
curves should be generated and compared. The melting peak at the melting temperature of 
the amplicon differentiates it from the artifacts with lower melting temperatures and 
broader smaller peaks
10,38
. EvaGreen
®
 outperforms SYBR
®
 Green, achieving high reaction 
efficiencies and giving higher and sharper peaks in melt curve analysis, due to the fact that 
it can be used at relatively high concentrations
56,57
. Also, EvaGreen
® 
is less inhibitory to 
PCR than SYBR
®
 Green and has a relatively low tendency to cause nonspecific 
amplification. Moreover, EvaGreen
®
 is very stable and spectrally compatible with existing 
PCR instruments
57
. 
The hydrolysis probes require a forward and a reverse primer, and their efficiency 
is dependent on the 5’ to 3’ exonuclease activity from Taq polymerase, for example. The 
fluorogenic non-extendable “TaqMan” probe has a covalently bonded fluorescent reporter 
dye attached at its 5’ end and a quencher dye attached to the 3’ end. When intact, the 
quencher is close to the reporter dye, decreasing the fluorescent signal, through 
fluorescence resonance energy transfer (FRET). However, during the real-time quantitative 
TaqMan
®
 assay, the fluorogenic probe hybridizes with the target sequence and, during the 
extension phase, is cleaved by the 5’ nuclease activity of Taq polymerase. The cleavage 
removes the probe from the target strand and separates the dyes, increasing the 
fluorescence of the reporter dye. At each cycle, more and more probes are cleaved, 
increasing the fluorescence intensity in a way that is directly proportional to the amount of 
generated fragments
38
. 
The method of dual hybridization probes requires two different oligonucleotides 
specific for the PCR product probes, in a tandem-like manner. The downstream probe 
carries a donor fluorophore at its 3’ end and the upstream probe has an acceptor 
fluorophore attached to its 5’ end. Each of the probes anneals with its respective target 
sequence in a head-to-tail manner, after denaturation. This way, the two fluorophores are 
brought closer in spatial proximity, allowing FRET. The donor dye transfers energy to the 
acceptor, that dissipates fluorescence at a different wavelength. As a consequence, this 
method is highly specific because the fluorescence only occurs when the two independent 
probe hybridize correctly to their target sequences
38,58
.  
In the same way as the hydrolysis probes, the molecular beacons have a fluorescent 
reporter dye attached at its 5’ end and a quenching compound attached to the 3’ end. 
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Figure 5 – Model of an amplification plot 
illustrating the mathematical basis of the 2
-ΔΔCt
 
method.  
This method allows relative quantitation through 
the measurement of cycle thresholds from the 
target and housekeeping genes of the test and 
control samples. Adapted from Vanguilder, H. 
D., Vrana, K. E. & Freeman, W. M. Twenty-five 
years of quantitative PCR for gene expression 
analysis. Biotechniques 44, 619–626 (2008). 
However, when near or below the annealing temperature and free in solution, the intact 
probe has the two ends base pairing to one another due to short complementary sequences, 
forming a hairpin or a stem-loop structure. As a result, the quencher is next to the reporter 
dye, decreasing the fluorescent signal, based on the FRET principle. During the annealing 
step, the loop portion, complementary to the target sequence hybridizes, causing a 
conformational change, and the stem is cleaved. Then, the dyes are separated and the 
quencher no longer decreases the reporter dye fluorescence, generating a fluorescent 
signal. At each cycle of the PCR, the molecular beacons rehybridize to the target sequence 
for fluorescence emission, indicating the amount of accumulated amplicon
10,38,58
.  
 
5) Quantitation Methods 
One of the methods to quantify real-time PCR results is the standard-curve or 
absolute quantitation, often used to measure 
a small number of genes in a few or many 
samples
47
. It is based on the plotting of a 
standard curve, constructed with the logs of 
copy numbers from standards with known 
quantities of initial DNA versus their 
corresponding Cts, which generates a 
straight line. Then, the Ct of the test samples 
is measured and compared with the standard 
curve, in order to determine the initial target 
amount
38
. In other words, the amount of 
product amplified from the test sample is 
compared with the amount of product 
amplified from standards with known 
quantities of initial DNA
10
.  
Another method of quantitation in 
qPCR is the relative quantitation or Delta 
Delta Ct method (2
-ΔΔCt
 method), which 
requires a reference control and a 
19 
housekeeping gene (Figure 5). First of all, if this method is applied, the results only are 
considered valid and reliable if the amplification efficiencies of the housekeeping and 
target genes are very similar and at or above 90%
38,40
. To guarantee that, a 10-fold serial 
dilution of a positive control template can be performed, followed by the plotting of the Ct 
as a function of log10 (concentration of template). The trend line slope (M) gives the PCR 
efficiency, through the function                 ⁄   , with –3,32 indicating an 
efficiency of 100%
47
. The relative expression levels of a target are calculated relative to a 
reference control (calibrator) through mathematical equations. The target amount of the 
sample is normalized to an endogenous housekeeping gene and relative to the normalized 
control. It is calculated by the formula
38
: 
      , 
where                            , 
and                                                     . 
 
Objectives 
The present work describes the development and validation of a qPCR method for 
CNVs detection. A qPCR-based methodology was developed to search for large deletions 
and/or duplications in genes in two situations: a) sequences which are not covered by 
aCGH or MLPA kits and b) confirmation or exclusion of previous MLPA and aCGH 
results.  
To accomplish that, initially the methodology was validated using samples with 
known results for the genes MECP2, NF1 and PARK2. Then, the method was developed in 
order to search for CNVs upon request. At the moment, 33 genes were assessed. The work 
flow begins with the selection of regions and primers design, followed by the primers 
validation. When the primers are validated, the samples are subjected to qPCR and the 
results analysed.  
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Methods 
Samples 
For validation of the study, 3 samples with normal copy number, 1 sample with a 
known deletion and 1 sample with a known duplication, all regarding the MECP2 gene, 
were used. Also, 5 samples with normal copy number for the tested fragment, 1 sample 
with a known deletion and 1 unknown sample were used for each NF1 and PARK2 genes. 
All samples were extracted from blood (EDTA) and studied previously by another method, 
such as MLPA, aCGH or other. 
For the development of the study 36 samples, extracted from blood (EDTA), were 
used as calibrators and/or normal samples. The calibrator samples were selected from 
genomic DNA samples with prior diagnosis of another disease without relation to CNVs of 
the tested fragment, which were beforehand studied by aCGH or MLPA. At first, in some 
cases, calibrator samples were commercial normal genomic DNAs, used in NGS or aCGH, 
and pools of 3 samples used for MLPA. After several tests it was decided that calibrator 
samples should be a pool of 3 normal samples. When the tested fragment was from a gene 
of the X chromosome, the calibrators were male pools if the test sample was male or 
female pools if the test sample was female. Also, 32 unknown samples, extracted from 
blood (EDTA) or, in some cases, purified genomic DNA, were tested for several genes.  
The negative control consisted of water, without template DNA, in order to check 
for primer-dimer and contaminations. All samples (Table S1, ANNEX I) were diluted with 
TE buffer to a concentration of 20ng/µL ±1,5ng/µL, and quantified in EPOCH (BioTek). 
 
Selection of Regions and Primers Design 
One region of the the ZNF80 gene and another of the GPR15 gene, having no 
CNVs described in the literature, were used as reference genes for normalization, during 
the relative quantitation
51–53
.  
The regions to be amplified in the test samples were selected based on the described 
gross deletions and gross insertions of the gene, recurring to The Human Gene Mutation 
Database (HGMD; http://www.hgmd.cf.ac.uk/), in order to ensure the detection of small 
deletions and duplications. The genes of interest were searched on the Ensembl Genome 
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Browser (http://www.ensembl.org/), with the organism “human” selected. Each gene 
sequence was downloaded in FASTA format and converted into Microsoft Office Word 
format for primer design.  
Primers were designed with the online program Primer3Plus 
(www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi), according to the following 
criteria: primer size of 18/20/22bp (minimum/optimal/maximum); GC content between 40 
and 60%; Tm of 58/60/62ºC (minimum/optimal/maximum); amplicon size of 
100/150/200bp (minimum/optimal/maximum). When not possible, primers were designed 
manually through the software Alamut Visual v. 2.8 rev. 1 (©2015 Interactive 
Biosoftware), following the same specifications as for Primer3Plus. The selected primers 
were analysed on the online program SNPCheck v3 
(http://secure.ngrl.org.uk/SNPCheck/snpcheck.htm), to verify that these did not target 
SNPs. The primers structure analysis, such as primers complementarity, hairpin formation 
and dimers, was made through the online program Oligo Analyzer 3.1 
(http://eu.idtdna.com/calc/analyzer), using default settings for qPCR, with the exclusion 
criterion of ΔG ≤ -9,0 kcal/mol and the software Oligo Analyzer 1.0.2 (Copyright© 2000-
2002 Teemu Kuulasmaa), with the exclusion criterion of ΔG ≤ -6,0 kcal/mol. To ensure 
primer specificity, primer sequences were run in the online program Primer search 2.52 
(http://bisearch.enzim.hu/) and in the UCSC In Silico PCR online tool 
(http://genome.ucsc.edu/cgi-bin/hgPcr), which also gave primers melting temperatures. 
The secondary structure of the amplicon sequences was predicted with the online program 
DNA Folding Form from The mfold Web Server (http://unafold.rna.albany.edu), using 
default settings and a temperature of 60ºC, with the exclusion criterion of ΔG ≤ -7,0 
kcal/mol. In order to predict the melting curve for each fragment, its sequence was inserted 
in the web-based application uMelt
SM
 – DNA Melting Curve Prediction 
(https://www.dna.utah.edu/umelt/um.php).  
The designed primers are summarized in Table S2 (ANNEX II); primers pairs for 
the ZNF80, MECP2, PLCB1, PARK2 and NF1 genes were supplied by Sigma-Aldrich and 
the remaining were supplied by Invitrogene, due to financial constraints. 
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Empirical Validation of Primers 
After in silico testing of primers, an empirical validation was performed, similar to 
the one described by D’haene and colleagues, in order to optimize primers41. To estimate 
qPCR efficiency, the standard curve is the most reliable and robust approach, broadly 
accepted by the scientific community
48
. A human normal genomic DNA dilution series 
(1:2 with 5 dilution points of 26ng/μL, 13ng/μL, 6,5ng/μL, 3,25ng/μL and 1,625ng/μL and 
a no-template control) was prepared and amplified. The concentrations of the dilution 
series were set in order to extend over the anticipated range of interest (18,5 – 21,5ng/μL) 
by at least 20%
48
. Assays were performed in duplicate, in a 20µL reaction volume, 
containing 4µL of 5x HOT FIREPol
®
 EvaGreen
®
 qPCR Mix Plus, 1µL of gDNA, 0,1-
1,0µL of forward and reverse primers at an initial concentration of 10nM (final 
concentration of 200nM) and DEPC Treated Water (Ambion, Life Technologies) up to the 
reaction volume. Reactions were performed in 0,1mL Strip Tubes in a 72-well rotor using 
the Rotor-Gene Q (Qiagen, Germany) detection system. Cycling conditions were 95ºC for 
15min, for initial activation step, followed by 40 cycles of 95ºC or 99ºC for 15sec, 60ºC 
for 20sec and 72ºC for 20sec. A standard curve was generated, with the evaluation of the 
amplification efficiency, coefficient of determination (R
2
) and slope. The PCR efficiency 
was considered satisfactory when between 90% and 110%, although in some cases an 
efficiency above 80% was accepted, and the R
2
 was considered suitable when not lower 
than 0,98, preferably over 0,99
41
. Afterwards, a melt curve analysis was performed to 
check the specificity of the PCR reactions. The Ct values were extracted and analysed with 
the Rotor-Gene Q software, version 1.7.94.  
The PCR programme with a melting temperature of 95ºC was used as standard. 
When the fragment melting curve prediction by the uMelt software was near or over 95ºC, 
the PCR program with a melting temperature of 99ºC was used for validation. Also, if a 
melting curve of a fragment first tested at 95ºC was highly close to 95ºC or the melting 
was incomplete, the same fragment was validated with a melting temperature of 99ºC. 
When the efficiency was lower than 80% or higher than 110%, the primers volume was 
increased or reduced, respectively, in the following validation run, until it was validated. 
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qPCR Assays for CNVs Detection 
All real-time qPCR assays were performed in a 20µL reaction volume, containing 
1µL of genomic DNA at an initial concentration of 20ng/mL, 4µL of 5x HOT FIREPol
®
 
EvaGreen
®
 qPCR Mix Plus, 0,1-1,0µL of forward and reverse primers at an initial 
concentration of 10nM (final concentration 200nM) and DEPC Treated Water (Ambion, 
Life Technologies) up to the reaction volume. Reactions were performed in 0,1mL Strip 
Tubes in a 72-well rotor using the Rotor-Gene Q (Qiagen, Germany) detection system. 
Cycling conditions were 95ºC for 15min, for initial activation step, followed by 40 cycles 
of 95ºC or 99ºC for 15sec, 60ºC for 20sec and 72ºC for 20sec. Primers volume and cycling 
conditions were used according to the ones used in the primers validation, when optimized. 
During validation of the method, the MECP2 experiment contained 2 calibrator 
samples (in duplicate), a sample with normal copy number (in duplicate), a sample with a 
known deletion (in duplicate), a sample with a known duplication (in duplicate), and a 
NTC (in duplicate). The experiments regarding the NF1 and PARK2 genes contained 2 
calibrator samples (in triplicate), a sample with normal copy number (in triplicate), a 
sample with a known deletion (in triplicate), an unknown sample (in triplicate), and a 
NTC. Throughout the method development, each experiment contained 3 calibrator 
samples (in triplicate), a sample with normal copy number (in triplicate), at least, a test 
sample (in triplicate), and a NTC. In order to test genes located at the X chromosome, the 2 
calibrator samples (in triplicate) and the sample with normal copy number (in triplicate) 
were pools of male samples only, since the test sample was male; also, we used a pool of 
female samples as a positive control (in triplicate), as well as a test sample (in triplicate), 
and a NTC. 
The copy number level of target genes was normalized to the ZNF80 or the GPR15 
gene. After PCR amplification, a melting curve was generated for each PCR product and 
analysed in order to ensure amplicons specificity. Data collection and analysis was 
performed through Rotor-Gene Q software, version 1.7.94, with the Ct values exported to 
Microsoft Office Excel. 
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Data Analysis and Statistics 
The data analysis was performed using the Microsoft Office Excel software, based 
on the method described by Hoebeeck and colleagues
52
. Reaction wells with obvious PCR 
reaction failure or clear outlier values (difference between Ct and mean Ct greater than 0,5) 
were excluded from data analysis. Copy number alterations were calculated according to 
the Delta Delta Ct method (2
-ΔΔCt
) and the samples were scored as normal, deleted or 
duplicated based on the scoring limits established. A haploid copy number of 1 is expected 
for a normal sample, a value of 0,5 for a sample with a deletion and a value of 1,5 for a 
sample with a duplication
22,59,60
.  
The expected cut-off values used were 0,7 for deletion upper limit
51–53
, 0,8 for 
normal lower limit
51–53
, 1,2 for normal upper limit
53
 and 1,25 for duplication lower limit
50
. 
As such, fragments with a haploid copy number below the deletion upper limit were scored 
as deleted, while fragments with a haploid copy number between the normal lower and 
upper limits were scored as normal, and finally fragments with a haploid copy number 
above the duplication lower limit were scored as duplicated. A fragment with an 
ambiguous haploid copy number was reanalysed. 
To determine the accuracy and to evaluate the precision of the qPCR approach, the 
haploid copy number values and their standard deviations for the deleted vs. control 
samples and duplicated vs. control samples were compared. In order to evaluate the 
equality of the two variances, a F test was performed (p-value < 0,05). If the two variances 
were not significantly different, then the two-sample t test for independent samples with 
equal variances was used; otherwise, a two-sample t test for independent samples with 
unequal variances was selected. The two-sample t-test was performed to evaluate if the 
copy numbers are significantly different between deleted and control samples as well as 
between duplicated and control samples (p-value < 0,05).  
At the end of all tests, based on the observed haploid copy number and the standard 
deviation, the limits for scoring a deletion, a normal copy number or a duplication were 
assessed. The mean value of the haploid copy number in deleted fragments plus two times 
the standard deviation was used as upper limit for scoring a deletion. For scoring a normal 
fragment, the mean value of the normal haploid copy number minus two times the standard 
deviation was used as lower limit and the mean value of the normal haploid copy number 
25 
plus two times the standard deviation was used as higher limit. Similarly, the mean value 
of the haploid copy number in duplicated fragments minus two times the standard 
deviation was used as lower limit for scoring a duplication.  
The qPCR results from the method validation were compared to previous results of 
MLPA, aCGH, Sanger sequencing and NGS, in order to evaluate the sensitivity (false-
negative results), specificity (false-positive results) and accuracy (true-value 
determination) of the qPCR approach. 
 
Results and Discussion 
Method Validation 
In order to validate the planned methodology, qPCR for the MECP2, NF1 and 
PARK2 genes were performed. The primers were designed according to the CNVs detected 
in the samples previously studied by another method and validated through the generation 
of a standard curve and melt curve analysis. The standard curve allowed the efficiency 
assessment of each primers’ pair (Figure 6). 
 
Figure 6 - Efficiency of the primers pairs for the MECP2, NF1 and PARK2 genes, used in 
the methodology validation. 
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The mean efficiency of the primers pairs was 0,88±0,07, with the primers pair for exon 14 
of the NF1 gene being the one with the lowest accepted efficiency (0,75). The primers pair 
MECP2_4B was discarded from the relative quantitation analysis, since it was 
considered not specific through the melt curve analysis. 
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1) The MECP2 gene 
Regarding the MECP2 gene, 3 samples with normal copy number (calibrators and 
samples A1), 1 sample with a known deletion (sample A4) and 1 sample with a known 
duplication (sample A5), were used. The MECP2 gene encodes a methyl-CpG binding 
protein, which is likely to be involved in transcriptional regulation. The most frequent 
mutation in the MECP2 are point mutations, small insertions or deletions
55
. Mutations in 
this gene are associated with Rett syndrome (MIM 312750), as well as with a severe 
neonatal form of encephalopathy (MIM 300673) and with X-linked syndromic mental 
retardation (MIM 300055, MIM 300260). The efficiency and specificity of each primers 
pair was evaluated through the generation of standard curves from a dilution series of DNA 
from two of the samples with normal copy number and a melting curve, respectively. 
Although primers MECP2_2 and MECP2_4C had efficiencies slightly below 90%, the 
initial cut-off value for acceptance, their melting curves showed specificity, and they 
followed to quantitative assay (Figure 6). The primer pair MECP2_4B was discarded from 
the subsequent quantitative assay, since it had a low efficiency in the standard curve from 
primers validation and the melt curve analysis showed that it was not specific. 
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Figure 7 - Relative quantitation of the MECP2 gene, during method validation. 
Sample A1 had a normal haploid copy number (1,01±0,08) for every primers pair. Sample A4 
presented a normal copy number (0,92±0,02) for exon 2 and the end of exon 4, as well as a 
heterozygous deletion (0,44±0,01) between exon 3 and part of exon 4. Sample A5 had a whole 
gene heterozygous duplication (1,47±0,07). 
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The results from the quantitative PCR (Figure 7) were concordant with the previous 
findings by aCGH and MLPA. Sample A1 had a normal haploid copy number (1,01±0,08) 
for every primers pair as expected, and MLPA was negative for deletions or duplications. 
Sample A4 showed a heterozygous deletion of exon 3 in the aCGH study and a 
heterozygous deletion of exon 3 and part of exon 4 in the MLPA. qPCR of this sample 
presented a normal copy number (0,92±0,02) for exon 2 and the end of exon 4, as well as a 
deletion (0,44±0,01) between exon 3 and part of exon 4. Also, sample A5 had a whole 
gene heterozygous duplication (1,47±0,07), in agreement with the heterozygous 
duplication detected by MLPA. Since the relative quantitation results were in agreement 
with previous results, the efficiency cut-off value for primers acceptance was redefined to 
80%. However, primers efficiency was still preferred between 90 and 110%. 
 
2) The NF1 gene 
Subsequently, the NF1 gene was tested, by analysing 3 samples with normal copy 
number, 1 sample with a known deletion and 1 unknown sample. The unknown sample, 
blinded for qPCR testing, was previously tested at another lab by NGS and qPCR, which 
reported a duplication of exon 13; however, the results of MLPA at this lab were negative 
for deletions or duplications of the NF1 gene. The Neurofibromin 1 (NF1) gene (OMIM* 
613113) is a tumour suppressor, located at 17q11.2 locus, which contains 57 constitutive 
coding exons and 3 alternative spliced exons over 280kb
61,62
. NF1 is a negative regulator 
of the oncogene Ras, being a Ras-GTPase activating protein and its loss is associated with 
increased formation of Ras-GTP leading to increased downstream signalling
63,64
. 
Heterozygous mutations in this gene cause neurofibromatosis type I (MIM 162200). Even 
though exon 14 primer pair had a low efficiency of 75% (Figure 6), all primers were 
considered validated, since the melt curve analysis indicated amplification of specific 
fragments.  
Sample A10 had a normal haploid copy number (0,99±0,04) for every pair of 
primers, as predicted, since it was a sample with a positive result for DMD deletion, and 
therefore it was not expected to have another deletion/duplication. Sample A11 showed a 
heterozygous deletion of the entire gene in the MLPA study. qPCR of this sample 
presented a heterozygous deletion (0,65±0,03) of all tested fragments. Furthermore, the 
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Figure 8 - Relative quantitation of the NF1 gene, during method validation. 
Sample A10 had a normal haploid copy number (0,99±0,04) for every primers pair. 
Sample A11 presented a heterozygous deletion (0,65±0,03) of all tested fragments. 
Sample A12 showed a normal copy number (0,99±0,07). 
blinded sample A12 showed a normal copy number (0,99±0,07), discordant with the 
results from another lab, however in agreement with the MLPA results. As such, the 
duplication of exon 13 was ruled out as a false-positive result. 
 
3) The PARK2 gene 
In order to test for the PARK2 gene, 3 samples with normal copy number, 1 sample 
with a known deletion and 1 unknown sample, were used. The unknown sample was 
previously tested by MLPA, which showed a heterozygous deletion of exons 4 to 7, but it 
was blinded for qPCR testing. The PARK2 gene (OMIM* 602544) encodes an E3 ubiquitin 
ligase, being located on chromosome 6, locus 6q25.2-q27
65,66
. Autosomal recessive 
juvenile Parkinson disease-2 (MIM 600116) is caused by homozygous or compound 
heterozygous mutation in this gene. PARK2 encompasses a genomic region of 1.3Mbp, 
consisting of 12 exons, and its 4.5kbp transcript contains a 1,395 bp open reading frame
65
. 
PARK2 is located within FRA6E, one of the most unstable common fragile sites of the 
human genome
65
. All primers were considered validated, since their efficiency was above 
80% (Figure 6) and the melt curve analysis indicated specific fragments amplification.  
Sample A10 had a normal haploid copy number (1,02±0,01) for every primers pair 
as expected, since it was a sample with a positive result for DMD deletion. Sample A13 
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showed a compound heterozygous deletion of exons 3 to 4 and 3 to 6 in the MLPA study 
and a sequencing failure of exons 3 and 4 after Sanger sequencing. qPCR of this sample 
presented a normal copy number (1.03±0,05) for exons 7 and 12, as well as a false 
homozygous deletion (0,00±0,00) of exon 4, since it cannot differentiate between a 
homozygous and a compound heterozygous deletion. Moreover, the blinded sample A14 
had a heterozygous deletion (0,55±0,09) of exons 4 and 7, but it had a normal copy number 
for exon 12, in agreement with the posteriorly known MLPA results. Therefore, the qPCR 
results were concordant with the previous findings for this gene either from MLPA or 
Sanger Sequencing. 
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Figure 9 - Relative quantitation of the PARK2 gene, during method validation. 
Sample A10 had a normal haploid copy number (1,02±0,01) for every primers pair. 
Sample A13 presented a normal copy number (1.03±0,05) for exons 7 and 12, as 
well as a false homozygous deletion (0,00±0,00) of exon 4. Sample A14 had a 
heterozygous deletion (0,55±0,09) of exons 4 and 7, but it had a normal copy 
number for exon 12. 
30 
4) Results comparison 
The qPCR results were compared to the previous results of aCGH, MLPA or other 
tests, in order to evaluate the sensitivity (false-negative results), specificity (false-positive 
results) and accuracy (true-value determination) of the qPCR approach. The total rate of 
concordant results was of 95%, the total rate of false-positive results was of 2,5%, and the 
rate of total false-negative results was of 2,5% (Figure 10). 
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Figure 10 - Evaluation of the accuracy, specificity and sensitivity of the developed 
methodology. 
qPCR and aCGH had 75% of their results in agreement, with the remaining 25% being 
false-negative aCGH results. MLPA and qPCR had all results consistent with each other. 
Other tests were 83% concordant with qPCR, however with a 17% rate of false positive 
results. Overall, qPCR had a total of 95% consistent results with other methods, as well as 
2,5% of false-positives and 2,5% of false-negative results 
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Reference Genes 
The relative quantitation method for CNVs detection requires the use of at least one 
reference gene for normalization
38
. The ZNF80 and GPR15 genes were selected to be used 
as reference genes for the developed method, since they possess two copies in the human 
genome and deletions or duplications are not described in the Human Gene Mutation 
Database®. Both genes are located on the long arm of chromosome 3
52
. The zinc finger 
protein 80 (ZNF80) (MIM 194553) gene is located at the 3q13.31 locus, and the G protein-
coupled receptor 15 (GPR15) (MIM 601166) gene is located at the 3q11.2 locus
51,54,67,68
. 
Both ZNF80 and GPR15 genes were validated at the melting temperatures of 95ºC 
and 99º C, with a mean efficiency of 0,89(±0,07) and a R
2
 of 0,9911 to 0,99708 (Figure 
11). During the relative quantitation for CNVs detection, ZNF80 was first used as the 
reference gene. When the mean haploid copy numbers calculated using the ZNF80 gene 
were in close proximity with the cut-off values or between the cut-off values for 
deletion/normal or normal/duplication, the tested fragments were re-tested using the 
GPR15 gene as reference gene. Both genes proved to be good candidate genes for 
normalization in the developed methodology. 
 
Primers validation 
In order to validate the designed 
primers, standard curves were retrieved 
for each primers pair, from qPCR assays 
of a dilution series of genomic DNA 
with normal copy number for the tested 
fragments. The efficiencies were 
considered acceptable when between 
90% and 110%, however, efficiencies 
over 80% were accepted in several cases. 
The R
2
, which indicates the 
reproducibility of the results, was 
accepted when superior to 0,98, even 
though it should be preferably over 0,99. 
1,00 
0,90 
0,83 0,84 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
ZNF80 
(95⁰C) 
ZNF80 
(99⁰C) 
GPR15 
(95⁰C) 
GPR15 
(99⁰C) 
E
ff
ic
ie
n
cy
 
Primers 
Primers Validation 
Figure 11 - Efficiency of the primers for the reference 
genes, using the cycling programs with melting 
temperatures of 95ºC and 99ºC. 
The mean efficiency of the primers pairs was 0,89±0,07, 
with the primers pair the GPR15 gene with lower 
efficiencies than the ones for ZNF80. 
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Nonetheless, in a few cases an inferior value had to be accepted.  
A melt curve was performed to evaluate the specificity of the primers pairs. The 
primers pairs with a single sharp peak in the melt curve were considered acceptable, since 
they show the amplification of only one fragment, and do not form primer dimers. Also, 
primers pairs with a melting curve according to the prediction by uMelt were accepted, 
since small sequences with a high CG ou AT content might cause small deviations of the 
peak. 
However, some primer pairs could not be validated since the efficiency was much 
higher than 110% or much lower than 80%, the R
2
 were too low and/or the melting curves 
showed a non-specific fragment or failure of amplification (Table 1). In these cases, 
primers were redesigned in the proximities of the first sequence. 
 
Table 1 - Efficiency, R
2
 and PCR conditions of the not validated primers. 
Primer Efficiency  R
2
 Primer Volume (µL) Melting Temperature (⁰C) 
CC2D1A_26 1,80 0,905 0,4 95 
COL6A1_12 2,66 0,781 0,4 99 
COL6A1_12v2 2,48 0,724 0,4 99 
COL6A1_35 0,36 0,890 0,4 95 
COL6A2_6 8,56 0,755 0,4 99 
COL6A2_29 2,20 0,943 0,2 95 
COL6A3_44 0,60 0,947 0,4 95 
SBF1_2 5,61 0,889 0,4 95 
SLC5A2_3 1,50 0,986 0,2 95 
 
In the end, 128 primer pairs were validated for the 33 genes that were assessed. The 
validated primers had a mean efficiency of 0,91±0,08 and a mean R
2
 of 0,99±0,01 (Figure 
12, Table S4).  
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Figure 12 – Efficiencies of the primers pairs of the tested genes. 
The mean efficiency of the primers pairs was 0,91±0,08, for the 33 tested genes. Primers were validated with a DNA dilution series of samples with normal copy 
number for the tested fragments. The efficiencies were acceptable when higher than 0,80, although in some primers pairs an inferior value had to be accepted. 
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Scoring limits 
For scoring a sample as having a deletion, a duplication or a normal copy number 
for the tested fragment, theoretical cut-off values were set. For the tested fragments, the 
cut-off values were set based on the values of previous studies, such as 0,7 for deletion 
upper limit
51–53
, 0,8 for normal lower limit
51–53
, 1,2 for normal upper limit
53
 and 1,25 for 
duplication lower limit
50
. At the time this methodology was initiated, no hemizygous 
duplication cut-off values were set theoretically. However, it was expected that the mean 
haploid copy number for a hemizygous duplication was approximately 2, since one copy 
would be represented as 1. Similarly, a homozygous deletion was expected to present a 
mean haploid copy number close to 0 (zero), since replication should not occur. 
In the future, for the next tested fragments, the mean values of the haploid copy 
number of fragments previously scored as deleted, duplicated and normal was used for the 
calculation of the cut-off values (Table S5; Table S6; Table S7). The mean value of the 
haploid copy number in deleted fragments plus two times the standard deviation is set as 
the upper limit for scoring a deletion. For scoring a normal fragment, the mean value of the 
normal haploid copy number minus two times the standard deviation is set as the lower 
limit and the mean value of the normal haploid copy number plus two times the standard 
deviation is set as the higher limit. However, since at this time no heterozygous 
duplications other than the ones used in the methodology validation were detected, the 
lower limit for scoring a duplication could not be readjusted. The mean haploid copy 
numbers of the Pool F (female pool), scored as duplicated for the fragments from the X 
chromosome genes BTK and NAA10 can be used to calculate the lower limit for a 
hemizygous duplication. 
At the moment, it is set that the values are: 0,67 for heterozygous deletion upper 
limit; 0,85 for normal lower limit and 1,15 for normal upper limit; 1,25 for heterozygous 
duplication lower limit; 1,84 for hemizygous duplication lower limit and 2,33 for 
hemizygous duplication upper limit (Table 2).  
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Table 2 - Scoring limits for scoring a deletion, duplication or normal copy number sample, based on the 
mean haploid copy numbers and standard-deviation of the test and control samples.  
Sample Type 
Mean Haploid Copy 
Number 
Standard-
deviation 
Lower 
Limit 
Upper 
Limit 
Normal 1,00 0,07 0,85 1,15 
Heterozygous Deletion 0,53 0,07 0,38 0,67 
Heterozygous Duplication - - 1,25 - 
Hemizygous Duplication 2,08 0,12 1,84 2,33 
 
Relative Quantitation for CNVs Detection 
Data analysis of the qPCR results from RotorGene-Q was performed using the 
Microsoft Office Excel software and copy number alterations were calculated according to 
the Delta Delta Ct method (2
-ΔΔCt
). This method allows the normalization of the test sample 
results through a normal copy number control (calibrator) and a housekeeping gene.  
During the implementation of the methodology, the majority of the analysed 
samples had a normal copy number for the tested gene fragments. One homozygous 
deletion was detected for the BCKDHA gene and heterozygous deletions were found in the 
COL6A1 and ABCA3 genes. Moreover, two genes from the X chromosome, BTK and 
NAA10, were assessed. Significant results are presented in more detail below. 
The comparison of the haploid copy number values for the deleted vs. control 
samples and duplicated vs. control samples, through the F test and two-sample t-test, 
allowed the determination of the statistical strength of the qPCR approach. The fragments 
analysed were considered statistically significant when p-value<0,05 and confidently 
assessed as deleted or duplicated. 
The results from the quantitative PCR showed that test fragments scored as normal, 
had a mean haploid copy number of 0,98±0,08, fragments scored as deleted (in 
heterozygosis) had a haploid copy number of 0,53±0,07 and fragments scored as 
duplicated (in hemizygosis) had a haploid copy number of 2,08±0,12. Moreover, the 
negative control samples used had a mean haploid copy number of 1,01±0,06. 
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1) Heterozygous deletion in COL6A1 gene 
The COL6A1, COL6A2 and COL6A3 genes encode three of the collagen VI chains, 
which is an important component of the extracellular matrix
69,70
. Mutations in each of the 
previous genes cause two main types of muscle disorders, being Ullrich congenital 
muscular dystrophy (UCMD) or Bethlem myopathy (BM)
70
. Although not very frequent, 
large deletions (deletions of exons 9 to 10, 9 to 13 and 9 to 14 and deletion of the exon 12) 
have been described in the COL6A1 gene, namely in association with Bethlem 
Myopathy
71
. Also, the COL6A2 gene can present some large deletions (deletion of intron 1, 
exons 1 to 18, exon 5, exons 5 to 8, intron 5 to exon 7, exons 6 to 10, exons 9 to 28, exon 
10, exon 11, exons 26 to 28, entire gene), mainly associated with UCMD
72
. Until present, 
no CNVs have been described for the COL6A3 gene
73
. 
The patient analyzed by us had a clinical suspicious of Bethlem myopathy or Ulrich 
congenital muscular dystrophy. Previous molecular studies for MYOT, Pompe, LMNA, 
CAV3 and SEP1 were negative. Also, immunohistochemical analysis was negative for 
sarcoglycans and dysferline. Moreover, the NGS panel for congenital muscular dystrophies 
did not detect any mutations in the analysed genes. Therefore, a deletion/duplication search 
through qPCR was requested for the COL6A1, COL6A2 and COL6A3 genes. 
A heterozygous deletion c.(1002+1_1003-1)_(1056+1_1057-1)del was detected in 
the COL6A1 gene. The detected variant is a deletion in heterozygosis which encompasses 
at least exon 14 of the COL6A1 gene. The result was first detected using the ZNF80 gene 
as the reference gene (Figure 13 - a) and the sample was re-tested for fragment using the 
GPR15 as reference gene (Figure 13 - b), which confirmed the deletion. This deletion is 
not described in the literature neither in databases of polymorphisms. Therefore, it was 
considered a variant of unknown clinical significance (VOUS) that could not confirm or 
exclude the clinical diagnosis of Bethlem myopathy. Nevertheless, the patient’s father is 
also affected and has a similar clinical presentation; being so, a recommendation was made 
in order to study the father to assess if the deletion segregates with the phenotype. 
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No deletions or duplications were detected in the remaining genes studied, COL6A2 
(Figure 14) and COL6A3 (Figure 15). Therefore, it was considered that these results did 
not allow us to attribute a genetic etiology to the patient clinical presentation. 
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Figure 13 - Relative quantitation for the COL6A1 gene. 
The pool of samples used as normal control showed a normal copy number (1,04±0,06). Sample A20 had a 
normal haploid copy number (0,94±0,07) for the primers pairs of exon 8, 9 and 33, as well as a heterozygous 
deletion of exon 14, using the ZNF80 as reference gene (left). The heterozygous deletion of exon 14 was 
confirmed using the GPR15 as reference gene (right). 
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Figure 14 - Relative quantitation for the COL6A2 gene 
Sample A17 used as normal control showed a normal copy number (1,00±0,10). 
Sample A20 had a normal haploid copy number (0,93±0,10) for all primers pairs. 
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2) Homozygous deletion in the BCKDHA gene 
The BCKDHA gene encodes the alpha subunit of the decarboxylase component of 
the branched-chain alpha-keto acid dehydrogenase (BCKD) complex. This complex 
catalyses the oxidative decarboxylation of the branched-chain α-ketoacids derived from the 
branched-chain amino acids leucine, isoleucine, and valine
74
. Maple Syrup Urine Disease 
(MSUD) (MIM #248600) is a rare autosomal recessive disorder of metabolism caused by 
the defective function of the mitochondrial BCKD. When one of the four catalytic 
subunits, encoded by nuclear genes (BCKDHA, BCKDHB, DBT and DLD), is functionally 
impaired the complex’s activity is reduced and the respective branched-chain α-ketoacids 
accumulate in body fluids to toxic levels
75
. HGMD reports 4 gross deletions (deletion of 
exons 2 to 4, deletion of exon 4, deletion of exon 6 and deletion of exons 5 to 8) and one 
gross duplication (duplication of exons 2 to 4) of the BCKDHA gene, all related to 
MSUD
76
. 
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Figure 15 - Relative quantitation of the COL6A3 gene. 
The pool of samples used as normal control showed a normal copy 
number (0,99±0,05). Sample A20 had a normal haploid copy number 
(1,02±0,08) for all primers pairs. 
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The patient under study had a clinical suspicion of MSUD. First, Sanger 
sequencing of the BCKDHB and BCKDHA genes were performed, which did not detect 
any mutations in the analysed regions. However, no amplification of exons 2 and 3 of the 
BCKDHA gene could be obtained. Subsequently, CNVs detection through qPCR was 
requested, which confirmed a homozygous deletion c.(108+1_109-1)_(375+1_376-1)del in 
the BCKDHA gene (Figure 16). This mutation is a novel deletion, not described in the 
literature, which includes at least exons 2 to 3 of the BCKDHA gene. Nonetheless, a similar 
deletion has been described in patients with maple syrup urine disease
77
. 
 
3) Heterozygous deletion in the ABCA3 gene 
The ATP-binding cassette A3 (ABCA3) gene is an 80kB gene mapped to human 
chromosome 16p13.3
78
. It encodes a 1704-amino-acid protein highly expressed in the lung, 
which has been localized to the limiting membrane of lamellar bodies, implicating ABCA3 
as possibly important in the maturation of lamellar bodies and surfactant production
79
. The 
concept that ABCA3 mutations disrupt surfactant homeostasis is supported by clinical and 
pathologic findings in patients with ABCA3 mutations, which present respiratory distress 
after birth associated with abnormally small lamellar body inclusions
78
. Bi-allelic 
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Figure 16 - Relative quantitation for the BCKDHA gene. 
The pool of samples used as normal control showed a normal copy number 
(0,99±0,03). Sample A53 had a normal haploid copy number (0,85±0,00) for 
primers pairs of exons 4 and 6, as well as a false homozygous deletion (0,02±0,01) 
of exons 2 and 3. 
40 
mutations of ABCA3 are the most frequent cause of surfactant metabolism dysfunction, 
pulmonary type 3 (MIM#610921)
80
. HGMD reports 2 gross deletions (deletion of exons 2 
to 5 and deletion of exon 12) of the ABCA3 gene, related to Lung disease and Fatal 
surfactant deficiency
81
.  
The patient had a clinical suspicion of pulmonary surfactant metabolism 
dysfunction, and a Surfactant Metabolism Dysfunction Panel (NGS panel) was requested. 
This panel detected the variant c.4442C>T (p.Ala1481Val), in apparent homozygosis, in 
the ABCA3 gene. However, no mutations were detected in the remaining genes analysed in 
this panel. The detected variant is not described in the literature, being located in a highly 
conserved residue and bioinformatic analysis suggests that it is probably a pathogenic 
variant. Therefore, it was considered a VOUS. Also, the study of the parents revealed that 
this variant is of paternal origin. 
Subsequently, a CNVs analysis through qPCR was performed. A heterozygous 
deletion c.(?_4910-1)_(4983+1_?)del was detected in the ABCA3 gene. The detected 
variant is a deletion in heterozygosis which encompasses at least exon 32 of the ABCA3 
gene and most likely will include exon 29, where the variant was detected. The result was 
first detected using the ZNF80 gene as the reference gene (Figure 17 - a) and the sample 
was re-tested for fragment using the GPR15 as reference gene (Figure 17 - b), which 
confirmed the deletion. This deletion is not described in the literature neither in databases 
of polymorphisms. Therefore, it was considered a VOUS.  
The qPCR result, together with the previous NGS panel result, might support the 
clinical diagnosis of pulmonary surfactant metabolism dysfunction type 3. Also, the 
apparent homozygous variant c.4442C>T (p.Ala1481Val) detected in the NGS panel 
corresponds, in fact, to a compound heterozygosity. Nevertheless, the study of the mother 
to confirm if she carries the detected deletion was recommended, as well as an additional 
qPCR to delimit the extent of the detected deletion. 
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4) CNVs search in genes from the X chromosome 
The Bruton’s tyrosine kinase (BTK) gene is localized on Xq21.3–Xq22, being a 
member of the Tec family of kinases
82
. X-linked agammaglobulinemia (XLA; MIM 
#300300) is a primary immunodeficiency caused by deleterious variations in BTK. XLA 
presents a drastic decrease in the number of B lymphocytes, a severe reduction of all 
immunoglobulin isotypes and recurrent bacterial and enteroviral infections. Therefore, the 
defect blocks B-lymphocyte development between the pro- and pre-B-cell stage
83
. HGMD 
reports several gross deletions and duplications of the BTK gene, mostly related to XLA, 
with a few related to BTK deficiency or Mohr-Tranebjaerg syndrome. Furthermore, the 
described deletions and duplications encompass almost every single exon of the gene
84
. 
The patient studied was a male with a clinical suspicion of XLA, for which it was 
requested both sequencing and deletion/duplication analysis of BTK gene. Sanger 
sequencing of the BTK gene was performed, which detected a hemizygous c.82C>T 
(p.Arg28Cys) variant, described in the literature and already reported in other patients and 
families with XLA
85
, confirming the clinical diagnosis of X-linked agammaglobulinemia 
type 1 caused by mutation in the BTK gene. On the other hand, CNVs detection through 
qPCR did not detect any deletions or duplications in the analysed regions (Figure 18).  
The pool of samples used as normal control showed a normal copy number (1,00±0,02). Sample A80 had a 
normal haploid copy number (0,98±0,04) for the primers pairs of exon 5, 12 and 22, as well as a 
heterozygous deletion of exon 32, using the ZNF80 as reference gene (left). The heterozygous deletion of 
exon 32 was confirmed using the GPR15 as reference gene (right). 
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Figure 17 - Relative quantitation for the ABCA3 gene. 
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Since it was a gene from the X chromosome and the test sample was male, the 
pools of samples used as calibrators, as well as the pool of samples used as normal control, 
only contained male samples. As expected, the later showed a normal copy number, so did 
the test sample, for all pairs of primers. Nevertheless, the positive control (pool of female 
samples) had a copy number of 2,05±0,17, accordingly with the predicted results, because 
female samples possess two X chromosomes, therefore the double of the BTK sequence. 
However, exon 19 showed normal copy number for the normal control and test samples, 
but a slightly lower relative quantitation for the female pool. This might be explained by 
germline mosaicism of at least one of the samples from the pool, or a side effect of the X-
chromosome inactivation
86,87
. 
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Figure 18 - Relative quantitation of the BTK gene. 
The pool of samples used as normal control showed a normal copy number (1,01±0,04), while POOL_F had a copy number of 2,05±0,17, confirming the 
duplication of the gene sequence. Sample A68 had a normal haploid copy number (0,97±0,05) for all primers pairs. 
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The NAA10 gene is localized at Xq28, and codes for the catalytic subunit of the 
hNaTA complex
88
. Pathogenic NAA10 mutations are related to Lenz microphthalmia 
syndrome (LMS, MIM 309800), intellectual disability, arrhythmia and developmental 
delays
89
. LMS is an X-linked, genetically heterogeneous disorder, characterized by 
unilateral or bilateral microphthalmia or anophthalmia and defects in the skeletal and 
genitourinary systems
88
. HGMD does not have any described deletions or duplications of 
the NAA10 gene
90
. 
The patient studied was a male with a clinical diagnosis of Lenz microphthalmia, 
with multiple studies, including a whole exome sequencing (WES), performed in another 
laboratory, with normal results. Therefore, deletion/duplication analysis of NAA10 gene 
was requested, which did not detect any deletions or duplications in the analysed regions 
(Figure 19). This result could not confirm the clinical diagnosis of syndromic type 1 (or 
Lenz) microphthalmia caused by deletions/duplications in the analysed regions of the 
NAA10 gene.  
 
In the same manner as the BTK gene, NAA10 is a gene from the X chromosome 
with a male test sample. Therefore, the calibrators and normal control pools only contained 
male samples. The normal control and the test sample showed a normal copy number. 
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Figure 19 - Relative quantitation of the NAA10 gene. 
The pool of samples used as normal control showed a normal copy number 
(1,01±0,01), while POOL_F had a copy number of 1,36±0,08. Sample A78 had a 
normal haploid copy number (1,08±0,09) for all primers pairs. 
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Again, the positive control had a mean haploid copy number slightly lower than expected, 
which also might be explained by germline mosaicism or a side effect of the X-
chromosome inactivation
86,87
. 
 
Conclusion 
This work allowed the development and validation of a methodology for CNVs 
detection in clinical diagnostics, through qPCR, using the relative quantitation method. The 
developed and optimized methodology proved to be accurate and specific, allowing the 
detection of autosomal homozygous and heterozygous deletions, heterozygous 
duplications, as well as deletions and duplications on fragments from the X chromosome. 
However, this methodology cannot differentiate compound heterozygous deletions 
from homozygous deletions. Also, it is sensitive to SNPs which may impair the primers 
annealing and subsequent PCR, as well as cause allele dropout. Pseudogenes or other 
highly homologous sequences might interfere with the technical ability of variant 
identification in this analysis. Moreover, secondary structures and sequences very rich in 
CGs might interfere with the efficiency of PCR.  
Therefore, the qPCR methodology requires a well-though planning, from selection 
of regions and primers design up to data analysis. The presented method is easily adaptable 
for the screening of CNVs in several genetic diseases. So, this approach may be 
implemented as the method of choice in routine DNA diagnosis for deletion/duplication 
analysis in genes for which there is no MLPA kit, as well as to confirmf CNVs in a 
particular gene, previously detected by another method (MLPA, aCGH, etc.).  
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ANNEX I – Samples 
Table S1 - Samples identification, matrix of extraction, CNV status and studied genes for the validation and development of the methodology. 
Sample  Matrix CNV Status Studied Gene Observations 
A1 DNA Normal MECP2 
 
A2 Blood (EDTA) Normal MECP2 
 
A3 Blood (EDTA) Normal MECP2 
 
A4 Blood (EDTA) Deleted MECP2 
 
A5 Blood (EDTA) Duplicated MECP2 
 
A6 Blood (EDTA) Normal PARK2; FANCC; COL6A2; VCP; DNMT3B; SBF1 Del SMN1 
A7 Blood (EDTA) Normal 
NF1; FANCC; COL6A1; CC2D1A; COL6A2; BCKDHA; SLC5A1; MMACHC; 
CD96; ASXL3; MYO15A; SLC5A2 
Del SMN1 
A8 Blood (EDTA) Normal NF1; PARK2; FANCC; COL6A2; MYO15A; SLC5A2; CC2D1A; SBF1 Del SMN1 
A9 Blood (EDTA) Normal NF1; PARK2; FANCC; RBM8A; SLC5A1 Del SMN1 
A10 Blood (EDTA) Normal NF1; PARK2; FANCC; VCP; DNMT3B Del DMD 
A11 Blood Deleted NF1 
 
A12 Blood (EDTA) Test NF1 
 
A13 Blood (EDTA) Deleted PARK2 
 
A14 Blood (EDTA) Test PARK2 
 
A15 Blood (EDTA) Normal COL6A1; COL6A3; COL6A2; MYO15A; ESCO2; ASXL3 Del SMN1 
A16 DNA Test FANCC 
 
A17 Blood (EDTA) Normal FANCC; COL6A2; THPO Del DMD 
A18 Blood (EDTA) Normal FANCC; COL6A2; CC2D1A; SLC5A2; SBF1; PEX1 Del NF1 
A19 Blood (EDTA) Normal FANCC; COL6A2; THPO; ESCO2 Del DMD 
A20 Blood (EDTA) Test COL6A1; COL6A2; COL6A3 
 
A21 Blood (EDTA) Normal IL7R; MVK; COL6A2; THPO; MGME1 Del DMD 
A22 Blood (EDTA) Normal MVK; THPO; MGME1; PEX1; COL6A1; COL6A3 Del DMD 
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(cont.) Table S1 - Samples identification, matrix of extraction, CNV status and studied genes for the validation and development of the methodology. 
Sample  Matrix CNV Status Studied Gene Observations 
A23 N/A Normal COL6A2; THPO; COL6A3; IL7R; MGME1; ESCO2; MYO15A; ASXL3 CT_NGS 
A24 N/A Normal COL6A2; THPO; COL6A3; IL7R; MGME1; ESCO2; MYO15A; ASXL3 CT_aCGH 
A25 DNA Test THPO 
 
A26 Blood (EDTA) Normal COL6A3; IL7R; MGME1; ESCO2; MYO15A POOL_M_MLPA 
A27 Blood (EDTA) Normal COL6A3; IL7R; MGME1; ESCO2; MYO15A POOL_M_MLPA 
A28 Blood (EDTA) Normal COL6A3; IL7R; MGME1; ESCO2; MYO15A POOL_M_MLPA 
A29 Blood (EDTA) Normal COL6A3; IL7R; MGME1; ESCO2; MYO15A POOL_F_MLPA 
A30 Blood (EDTA) Normal COL6A3; IL7R; MGME1; ESCO2; MYO15A POOL_F_MLPA 
A31 Blood (EDTA) Normal COL6A3; IL7R; MGME1; ESCO2; MYO15A POOL_F_MLPA 
A32 Blood (EDTA) Test IL7R 
 
A33 Blood (EDTA) Test MGME1 
 
A34 DNA Test ESCO2 
 
A35 Blood (EDTA) Test MYO15A 
 
A36 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; 
SLC5A2; VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; 
MARVELD2; GYG1; SMARCA4; NAA10; ESCO2 
POOL_M 
A37 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; 
SLC5A2; VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; 
MARVELD2; GYG1; SMARCA4; NAA10; ESCO2 
POOL_M 
A38 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; 
SLC5A2; VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; 
MARVELD2; GYG1; SMARCA4; NAA10; ESCO2 
POOL_M 
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(cont.) Table S1 - Samples identification, matrix of extraction, CNV status and studied genes for the validation and development of the methodology. 
Sample  Matrix CNV Status Studied Gene Observations 
A39 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; MARVELD2; 
GYG1; SMARCA4; NAA10; ESCO2 
POOL_F 
A40 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; MARVELD2; 
GYG1; SMARCA4; NAA10; ESCO2 
POOL_F 
A41 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; MARVELD2; 
GYG1; SMARCA4; NAA10; ESCO2 
POOL_F 
A42 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; BTK; MARVELD2; 
GYG1; SMARCA4; ESCO2 
POOL_3 
A43 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; MARVELD2; GYG1; 
SMARCA4; ESCO2 
POOL_3 
A44 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; MARVELD2; GYG1; 
SMARCA4; ESCO2 
POOL_3 
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(cont.) Table S1 - Samples identification, matrix of extraction, CNV status and studied genes for the validation and development of the methodology. 
Sample  Matrix CNV Status Studied Gene Observations 
A45 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; MARVELD2; GYG1; 
SMARCA4; ESCO2 
POOL_4 
A46 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; MARVELD2; GYG1; 
SMARCA4; ESCO2 
POOL_4 
A47 Blood (EDTA) Normal 
ASXL3; PEX1; MVK; FANCC; COL6A1; SLC5A1; BCKDHA; MYO15A; 
COL6A2; MMACHC; SAG; ADAMTS2; CC2D1A; ERCC3; FBN2; SLC5A2; 
VCP; CD96; SBF1; ITPR1; DNMT3B; IL7R; THPO; MARVELD2; GYG1; 
SMARCA4; ESCO2 
POOL_4 
A48 Blood (EDTA) Test ASXL3 
 
A49 Blood (EDTA) Test ASXL3 
 
A50 DNA Test PEX1; MVK 
 
A51 Blood (EDTA) Normal 
FBN2; MMACHC; ASXL3; BCKDHA; ADAMTS2; SAG; COL6A2; SLC5A2; 
COL6A1; ERCC3; FANCC  
A52 DNA Test SLC5A1 
 
A53 Blood (EDTA) Test BCKDHA 
 
A54 Blood (EDTA) Test MMACHC 
 
A55 Blood (EDTA) Test SAG 
 
A56 Blood (EDTA) Test ADAMTS2 
 
A57 Blood (EDTA) Test CC2D1A 
 
A58 Blood (EDTA) Test ERCC3 
 
A59 Blood (EDTA) Test FBN2 
 
A60 Blood (EDTA) Test SLC5A2 
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(cont.) Table S1 - Samples identification, matrix of extraction, CNV status and studied genes for the validation and development of the methodology. 
Sample  Matrix CNV Status Studied Gene Observations 
A61 Blood (EDTA) Test VCP 
 
A62 Blood (EDTA) Test CD96 
 
A63 Blood (EDTA) Test SBF1 
 
A64 Blood (EDTA) Test ITPR1 
 
A65 Blood (EDTA) Test DNMT3B 
 
A66 Blood (EDTA) Test IL7R 
 
A67 DNA Test THPO 
 
A68 DNA Test BTK 
 
A69 Blood (EDTA) Normal BTK; NAA10 POOL_M1_MLPA 
A70 Blood (EDTA) Normal BTK; NAA10 POOL_M1_MLPA 
A71 Blood (EDTA) Normal BTK; NAA10 POOL_M1_MLPA 
A72 Blood (EDTA) Normal BTK; NAA10 POOL_M2_MLPA 
A73 Blood (EDTA) Normal BTK; NAA10 POOL_M2_MLPA 
A74 Blood (EDTA) Normal BTK; NAA10 POOL_M2_MLPA 
A75 Blood (EDTA) Test MARVELD2 
 
A76 DNA Test GYG1 
 
A77 Blood (EDTA) Test SMARCA4 
 
A78 Blood (EDTA) Test NAA10 
 
A79 Blood (EDTA) Test MCCC2  
A80 Blood (EDTA) Test ABCA3  
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ANNEX II -Primers 
Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
ZNF80_1-F GTGGCAGTAGGAAAGCTGTG 20 58,5 133 NM_007136.3 
ZNF80_1-R AGTTCTCTGACGTTGACTGATG 22 57,0 133 NM_007136.3 
MECP2_2-F CCCAGAATACACCTTGCTTCT 22 58,3 119 NM_004992 
MECP2_2-R GGCCAAACCAGGACATATACTA 22 58,0 119 NM_004992 
MECP2_3-F GGTCCAAGCCTGCCTCTG 18 62,0 186 NM_004992 
MECP2_3-R CTCATGCTTGCCCTCTTTC 19 58,5 186 NM_004992 
MECP2_4A-F CATCCGCTCTGCCCTATCT 19 60,3 150 NM_004992 
MECP2_4A-R AGGGATGTGTCGCCTACCT 19 59,5 150 NM_004992 
MECP2_4B-F GAGAAGAGCGGGAAAGGAC 19 59,0 118 NM_004992 
MECP2_4B-R GGTGGTGGTGCTCCTTCT 18 58,6 118 NM_004992 
MECP2_4C-F ACATTGTTTCATCCTCCATGC 21 59,8 164 NM_004992 
MECP2_4C-R TCAGAGCCCTACCCATAAGG 20 59,1 164 NM_004992 
PARK2_4-F TTCTCCAGCAGGTAGATCAATC 22 58,4 152 NM_004562.2 
PARK2_4-R TGCTGACACTGCATTTCCTT 20 59,4 152 NM_004562.2 
PARK2_7-Fv2 CCTCCAGGATTACAGAAATTGG 22 59,8 115 NM_004562.2 
PARK2_7-Rv2 TGCACTGGAAAACCAGGA 18 58,7 115 NM_004562.2 
PARK2_12-F GCTCAGAAAGTGATGTCTAGGC 22 58,2 163 NM_004562.2 
PARK2_12-R ACAGTTCCAGCACCACTCG 19 59,9 163 NM_004562.2 
NF1_13-F ACAGACCTGGAGACAAGAAGC 21 58,5 151 NM_000267.3 
NF1_13-R GGCGTTTCAGCTAAACCC 18 58,3 151 NM_000267.3 
NF1_14-F CCTTGCAGAATCCAAGAAAAC 21 58,8 148 NM_000267.3 
NF1_14-R GAACATGGAATTCATTTTCCC 21 58,2 148 NM_000267.3 
NF1_58-F CGACACATGACTGCAATGAA 20 59,2 173 NM_000267.3 
NF1_58-R CTTCTTTGCTTCTGCACTTGG 21 60,2 173 NM_000267.3 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
FANCC_1-F CCAGAATGCACTGCTGACAC 20 60,5 106 NM_000136.2 
FANCC_1-R AATTTGGCTTTGCCTCGTATT 21 60,0 106 NM_000136.2 
FANCC_2-F CACTTTGGAAACCCAGCAA 19 59,7 166 NM_000136.2 
FANCC_2-R GTGGCATTCTGTCTTGGTGA 20 59,7 166 NM_000136.2 
FANCC_4-F CCTTTTTGTAGATGAAAGCCAA 22 58,4 140 NM_000136.2 
FANCC_4-R TCAAAGAAGTGCAGAGCAAGA 21 58,9 140 NM_000136.2 
FANCC_15-F GTCCCTGGACAAAGGACAAA 20 59,9 120 NM_000136.2 
FANCC_15-R CTGGTCAAGAAAGCCAATGA 20 58,8 120 NM_000136.2 
COL6A2_i1-F GCCGCTGCCATCAGTAAT 18 59,8 173 NM_001849.3 
COL6A2_i1-R CAAGGACAAGCACTTCATGC 20 59,4 173 NM_001849.3 
COL6A2_5-F ACCCATGCAACCTTCTGTC 19 58,5 123 NM_001849.3 
COL6A2_5-R AGGTAATCTGGGCATCTTACCT 22 58,2 123 NM_001849.3 
COL6A2_7-F GCTCACACTGCTGCGTTGT 19 61,3 199 NM_001849.3 
COL6A2_7-R TGCTTCTGTTCCTTGGTAACTG 22 59,4 199 NM_001849.3 
COL6A2_10-F TTCCTTCTCTCTTCAGGGGG 20 60,7 113 NM_001849.3 
COL6A2_10-R CTGGGATGCCTCTGTGAGAC 20 60,8 113 NM_001849.3 
COL6A2_11-F GGCTGTGTCTTGGTCGTTG 19 60,3 127 NM_001849.3 
COL6A2_11-R GTTTCCAGGGTCTCCCTTG 19 59,5 127 NM_001849.3 
COL6A2_29-F GAATGGAAGGGCACAGGTG 19 61,5 101 NM_001849.3 
COL6A2_29-R TGCCACGGACAGCTCTGT 18 61,7 101 NM_001849.3 
COL6A1_8-F AACCTGAGTCTGGGGTCCT 19 58,5 108 NM_001848.2 
COL6A1_8-R GCAGGAGTCACCACTCACC 19 59,2 108 NM_001848.2 
COL6A1_9-F CCCAACCTTGACCTGTTTTG 20 60,4 185 NM_001848.2 
COL6A1_9-R ACTTTGGCACTCAGAACCCA 20 60,7 185 NM_001848.2 
COL6A1_12-F CACTGTCAGTCCCCATGATTC 21 60,4 178 NM_001848.2 
COL6A1_12-R CTCACCTTGTAGCCCTTGGG 20 61,9 178 NM_001848.2 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
COL6A1_35-F CAGACAGTCTCCAGGAAGGTG 21 59,9 119 NM_001848.2 
COL6A1_35-R GGAAAATTCGCATCACATTTT 21 58,9 119 NM_001848.2 
COL6A3_1-F ACGCAGTGAGTGGGAAAAGT 20 59,8 124 NM_004369.3 
COL6A3_1-R CCCAAACCTGGAAAAACAGA 20 59,9 124 NM_004369.3 
COL6A3_16-F GTGCTGCTCTGCCAAATG 18 59,1 113 NM_004369.3 
COL6A3_16-R CTTCTCCAGGAATACCCTGAA 21 58,3 113 NM_004369.3 
COL6A3_44-F GTGCCCTTTTGGGTCAGTAA 20 60,0 177 NM_004369.3 
COL6A3_44-R ATGGCTGACTCCTTCTTCTTCA 22 60,4 177 NM_004369.3 
IL7R_3-F GAACATGCCTCCACTCACC 19 59,0 154 NM_002185.3 
IL7R_3-R GCCCCACTGTAGGAATAAAAAG 22 59,1 154 NM_002185.3 
IL7R_8-F CCTGACATTGAACCCAGTTG 20 59,0 191 NM_002185.3 
IL7R_8-R GCTGTGAGGGAGACTAGGAACT 22 59,0 191 NM_002185.3 
THPO_3-F AACTGCAAGGCTAACGCTGT 20 60,1 123 NM_000460.3 
THPO_3-R GGGATAATGTTGGGAGTTCTCA 22 60,2 123 NM_000460.3 
THPO_4-F CAGAGGTTCACCCTTTGCCTA 21 61,5 101 NM_000460.3 
THPO_4-R CAAGGTTAGGGATGGCTTTCTT 22 60,8 101 NM_000460.3 
THPO_6-F CCCCTACCAGCCCTCTTCTA 20 60,6 179 NM_000460.3 
THPO_6-R GGCTTTGGGTTTCAGGAGA 19 60,2 179 NM_000460.3 
MGME1_2-F ACAGCGGATGATTCTGGAAC 20 60,1 126 NM_052865.3 
MGME1_2-R CATTCTTTTGACACCGTTGC 20 59,2 126 NM_052865.3 
MGME1_3-F AAGTGCTGTTCAACATGAAACC 22 59,1 174 NM_052865.3 
MGME1_3-R GCACAAAGGTCTGGACATTAAA 22 59,1 174 NM_052865.3 
MGME1_5-F TGCCCTGGAGTAAGAAGGAA 20 59,8 186 NM_052865.3 
MGME1_5-R GAAGAAGCCACTTGGTCCAG 20 59,8 186 NM_052865.3 
PEX1_6-F TCAGGATAACTCCAGTGGAAGTT 23 59,2 140 NM_000466.2 
PEX1_6-R GCTAAAGCAACTAGAAATCTTACAAAA 27 58,1 140 NM_000466.2 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
PEX1_9-F GCAACTGTAGGTCCTTCTAGATCC 24 59,7 165 NM_000466.2 
PEX1_9-R TTACATTGAAAACTCTGCCAGAT 23 58,0 165 NM_000466.2 
PEX1_12-F GTGCTTTCAAAAGGACAACCTG 22 61,0 149 NM_000466.2 
PEX1_12-R ACAGATGGCTGCATCCACA 19 61,3 149 NM_000466.2 
PEX1_14-F TTTACTTAAGGAGGACGAATCCA 23 59,2 123 NM_000466.2 
PEX1_14-R CAGTCATCTTCACTAATGGATGG 23 58,6 123 NM_000466.2 
PEX1_24-F GCTTTCAAAATCCAAAGAGGA 21 58,4 139 NM_000466.2 
PEX1_24-R GTTACAACATATGGAAAAGCCATC 24 58,9 139 NM_000466.2 
MVK_3-F CAATGGGAAAGTGGACCTCA 20 60,9 144 NM_000431.3 
MVK_3-R CTGCCCTCTCTGTAGGCTCTT 21 60,2 144 NM_000431.3 
MVK_4-F CATCCATGTTCCAATTCCAGT 21 59,7 113 NM_000431.3 
MVK_4-R TTGCTCTGTTCCACAGGCA 19 61,6 113 NM_000431.3 
MVK_6-F CAGGTGGACCAAGGAGGA 18 59,6 188 NM_000431.3 
MVK_6-R AGCACAGACTCTTGGGCA 18 58,0 188 NM_000431.3 
MYO15A_2-F AAGCTGGCGGAACAAGGTAT 20 61,0 121 NM_016239.3 
MYO15A_2-R AAGCAGCCTCTCTCCAAGGT 20 60,5 121 NM_016239.3 
MYO15A_16-F CAGGACCTGAGCTTCAACAG 20 58,6 101 NM_016239.3 
MYO15A_16-R ACCTGCTCCTCCTGGAAGA 19 59,9 101 NM_016239.3 
MYO15A_30-F CACAATGCCCACAATGCT 18 59,0 107 NM_016239.3 
MYO15A_30-R AGTCCCACTCACTTGAGAAGG 21 58,4 107 NM_016239.3 
MYO15A_45-F CCTGCATCACAGCCTGTTC 19 60,4 152 NM_016239.3 
MYO15A_45-R TGTGCCTCTGACTGGTTGC 19 61,1 152 NM_016239.3 
MYO15A_66-F CTCCACCTATCTCCCAACCA 20 59,9 124 NM_016239.3 
MYO15A_66-R ACCACACGACACAGTTCCAG 20 59,6 124 NM_016239.3 
ESCO2_2-F CCTCCCAGAAAATAGGGTTTT 21 58,5 201 NM_001017420 
ESCO2_2-R CACAGGCTGAGATTCACCTG 20 59,4 201 NM_001017420 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
ESCO2_7-F TGCAGCATGTACAGCATCAC 20 59,4 129 NM_001017420 
ESCO2_7-R GGTGGTAGAGGTGGTGGAAA 20 59,8 129 NM_001017420 
ESCO2_11-F TTGCTTCATGTTTGGCTGTT 20 59,3 107 NM_001017420 
ESCO2_11-R GGAAATTAGGGGTGTTGCAG 20 59,4 107 NM_001017420 
ASXL3_2-F TAAAAGCCCCTTCCCCTCTA 20 60,0 152 NM_030632.2 
ASXL3_2-R CTGCTTTGCTGTCATTGGTG 20 60,4 152 NM_030632.2 
ASXL3_11-F GAAAAGCCCAGCTTCTCCA 19 60,5 179 NM_030632.2 
ASXL3_11-R CATCCTGGCATTCACAGATACT 22 59,1 179 NM_030632.2 
CC2D1A_2-F AGCCATGTGGTGAACCAAAG 20 61,0 189 NM_017721.4 
CC2D1A_2-R TCACCTTTGCCTTTGAGCTT 20 60,0 189 NM_017721.4 
CC2D1A_14-F ACTGCGAGCCAAGCAGAA 18 60,9 138 NM_017721.4 
CC2D1A_14-R CACAAGCCCAGAAGGTTCAC 20 60,7 138 NM_017721.4 
CC2D1A_16-F GACTCACTGCCTTCTGTTTCC 21 58,9 118 NM_017721.4 
CC2D1A_16-R GGTGCAAGTGTCTGGCAC 18 58,7 118 NM_017721.4 
CC2D1A_28-F CTACCTGCTGAATGCCCATC 20 60,6 101 NM_017721.4 
CC2D1A_28-R CCACCCCATCTCCTAAGCT 19 59,1 101 NM_017721.4 
COL6A1_12v2-F CTCCCCACCCCAAATACC 18 60,0 148 NM_001848.2 
COL6A1_12v2-R AAGGCAGGAGTCAGATGCA 19 59,5 148 NM_001848.2 
COL6A3_43-F TGGATCACAGAAAGAATGTGAA 22 58,2 192 NM_004369.3 
COL6A3_43-R GGGTTGTATTTGAACGTCTTCC 22 59,7 192 NM_004369.3 
CD96_2-F CTCATGGCTCATGTTCTTTCTT 22 58,5 184 NM_198196.2 
CD96_2-R GGATGATAGACAGCAATCAGGT 22 58,1 184 NM_198196.2 
CD96_15-F GTGTGTGCATAAGACTCCCTCA 22 60,2 124 NM_198196.2 
CD96_15-R GGCTCTTGAATGCAAGTGTACT 22 58,5 124 NM_198196.2 
COL6A2_6-F TCAGAGGAGCTGTGGCAG 18 58,7 135 NM_001849.3 
COL6A2_6-R CCTGTCTTCCCTTCTGGC 18 58,3 135 NM_001849.3 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
SLC5A2_3-F AGCCCTGCTCACTCCCTC 18 60,5 123 NM_003041.3 
SLC5A2_3-R CAGCAACAGCCAAGCCAC 18 61,6 123 NM_003041.3 
SLC5A2_14-F CCAGTGCCTGCTCTGGTT 18 60,0 116 NM_003041.3 
SLC5A2_14-R GGTCCTCGCTGATGTCCT 18 58,7 116 NM_003041.3 
FBN2_2-F CGCTTGTCCATCACAGGC 18 61,4 118 NM_001999.3 
FBN2_2-R ATCCCTGCCAAGCACTCA 18 60,4 118 NM_001999.3 
FBN2_23-F GGAAGTAGGACCACACCTGCT 21 60,6 182 NM_001999.3 
FBN2_23-R CAGTCCCATCCAACGTAAGG 20 60,4 182 NM_001999.3 
FBN2_65-F CCCAAATCATTTCCTGTTCTTC 22 59,8 131 NM_001999.3 
FBN2_65-R GCCTTAGTTCCAGGATGTGCT 21 60,6 131 NM_001999.3 
ADAMTS2_3-F CCGTGTGCATGTGGTGTATC 20 60,9 108 NM_014244.4 
ADAMTS2_3-R GCTCTCCACACAGCCTGC 18 60,7 108 NM_014244.4 
ADAMTS2_13-F GATGCCACCTGTACTGCG 18 58,8 111 NM_014244.4 
ADAMTS2_13-R GCACACAGAGGCTGAAGG 18 58,0 111 NM_014244.4 
ADAMTS2_22-F CCAAGGCGACAAGTCAATATT 21 59,1 113 NM_014244.4 
ADAMTS2_22-R TGGTGAGGTTGTTGTACAGGTT 22 59,4 113 NM_014244.4 
MMACHC_1-F GCTCAGCGTGTAACGTGC 18 59,1 110 NM_015506.2 
MMACHC_1-R AAACTAACCTGGAAGGGGTAAA 22 58,1 110 NM_015506.2 
MMACHC_2-F CTCAAGCCCTTCTTGCAGA 19 59,3 147 NM_015506.2 
MMACHC_2-R GAGGAACTGGAGGCAGCT 18 58,0 147 NM_015506.2 
MMACHC_4-F GGACCTCCATGACCTTGCT 19 60,1 113 NM_015506.2 
MMACHC_4-R CCTGGCAGCAGCACTACC 18 60,6 113 NM_015506.2 
SLC5A1_2-F AGGTATGTCCTTTTGGCTGG 20 59,1 120 NM_000343.3 
SLC5A1_2-R CTGCCAGGAAGAAGCCTC 18 58,6 120 NM_000343.3 
SLC5A1_15-F CCTATGACCTATTTTGTGGGCT 22 59,4 148 NM_000343.3 
SLC5A1_15-R GTCACCAGGATGATGCCA 18 58,9 148 NM_000343.3 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
COL6A2_26-F GGCGTGGTGCAGTACAGC 18 61,7 153 NM_001849.3 
COL6A2_26-R GTAGGCAAACTTGAGGGCTGA 21 61,5 153 NM_001849.3 
BCKDHA_2-F CTGGGTGCTGCTTCTGATG 19 60,6 178 NM_000709.3 
BCKDHA_2-R GGTAGATGGGGATTCCAGAGA 21 60,3 178 NM_000709.3 
BCKDHA_3-F AGGAGAAGGTGCTGAAGCTC 20 58,8 138 NM_000709.3 
BCKDHA_3-R ACAGGTAGGGGACCTCAGGT 20 59,8 138 NM_000709.3 
BCKDHA_4-F GCAGGATTTGGATGGCTC 18 59,1 100 NM_000709.3 
BCKDHA_4-R TTGGTCATGTAGAAGGAGATCC 22 58,1 100 NM_000709.3 
BCKDHA_6-F ATGCCAACAGGGTCGTCA 18 61,1 101 NM_000709.3 
BCKDHA_6-R GATGGGGCACTCAAGTGTG 19 60,1 101 NM_000709.3 
COL6A1_14-F AGGGCACCAAGTCTGACAG 19 58,8 211 NM_001848.2 
COL6A1_14-R ACAGAAGTCAAAACGGTCCAC 21 59,1 211 NM_001848.2 
COL6A1_33-F CATCCCAGGCTCAGACCA 18 60,8 131 NM_001848.2 
COL6A1_33-R TGACATTCTTCAGGAAGGCAT 21 59,7 131 NM_001848.2 
SAG_2-F GCACAGGATCTCGTGAGTAGG 21 59,9 136 NM_000541.4 
SAG_2-R CATGTTATCTGTCCCTGGCA 20 59,5 136 NM_000541.4 
SAG_16-F GAGTTTGCTCGCCATAATCTG 21 59,9 128 NM_000541.4 
SAG_16-R CGTTGCACTGGTAACTACAGGT 22 59,2 128 NM_000541.4 
MYO15A_3-F CTCTCACACAGATGCACTCCA 21 60,0 105 NM_016239.3 
MYO15A_3-R TGCCCACTCACTCCAGCT 18 60,6 105 NM_016239.3 
ASXL3_3-F AGAAGCTGTACCTCAGACTGCTT 23 58,9 141 NM_030632.2 
ASXL3_3-R CTGACTTTCCAGGGATTTTGA 21 59,2 141 NM_030632.2 
ASXL3_8-F ACCAAAGCTGAGGACATTGAC 21 59,2 149 NM_030632.2 
ASXL3_8-R TGCCTATCCACTTCTGGGAG 20 60,2 149 NM_030632.2 
ASXL3_12-F GAAGAGAGTCCCTGGTGCAG 20 60,0 161 NM_030632.2 
ASXL3_12-R GCAATGGAAGCCTGTTGATT 20 60,1 161 NM_030632.2 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
FANCC_14-F ACCTCCTGGCAATGTCCAG 19 61,1 126 NM_000136.2 
FANCC_14-R AGTTGAGGAGAAGGTGCCTGA 21 61,3 126 NM_000136.2 
ERCC3_2-F AGAAATCCAGGAAGCGGC 18 60,3 129 NM_000122.1 
ERCC3_2-R CATCCACTTTGGTGCCTGA 19 60,7 129 NM_000122.1 
ERCC3_8-F CCAGTTCAAGATGTGGTCCAC 21 60,4 113 NM_000122.1 
ERCC3_8-R CCAGCATGGAGTAGGTGCTAA 21 60,3 113 NM_000122.1 
ERCC3_14-F AGAGCAACAGCAGCTCTTACAG 22 59,1 104 NM_000122.1 
ERCC3_14-R TACTCACCTGGCTGGATCTG 20 58,8 104 NM_000122.1 
SLC5A1_7-F TAGACAGGTCACCCTCCACA 20 59,1 122 NM_000343.3 
SLC5A1_7-R GATTAAAGACCCCACCAGCA 20 59,9 122 NM_000343.3 
SLC5A1_i14-F AGGAGCTGTTCAGACCAGTTCT 22 59,6 101 NM_000343.3 
SLC5A1_i14-R GTCTGGCTGGCATGATTCA 19 60,8 101 NM_000343.3 
GPR15_1-F TTCCTGACTGGAGTGCTGG 19 60 169 NM_005290.3 
GPR15_1-R TCCACAGTCCTAGAGATGCTTC 22 58,6 169 NM_005290.3 
VCP_2-F AGGTGATGACCTATCAACAGCC 22 60,4 112 NM_007126.3 
VCP_2-R GCTTACCTGGGACAAGGACAC 21 60,9 112 NM_007126.3 
VCP_8-F GCTGGTGAGTCTGAGAGCAA 20 59,3 134 NM_007126.3 
VCP_8-R TATCCCCTCAGGTAAGCTCCT 21 59,2 134 NM_007126.3 
VCP_16-F GGAGGTAGAAGAGGATGATCCA 22 59,5 137 NM_007126.3 
VCP_16-R GACTCTGCTGAAGGGTCTGG 20 60 137 NM_007126.3 
DNMT3B_3-F ACTCTCCAAGAGGGAGGTGTC 21 59,7 103 NM_006892.3 
DNMT3B_3-R CGTGATGAAAGCCAAAGACA 20 59,8 103 NM_006892.3 
DNMT3B_11-F ACGACTCAGCCACCTCTGAC 20 60,5 103 NM_006892.3 
DNMT3B_11-R TCACCTCGGCTCTGATCTTC 20 60,5 103 NM_006892.3 
DNMT3B_22-F ACAGACAATAACCACCAAGTCG 22 59 118 NM_006892.3 
DNMT3B_22-R CCTTGCTCACCTTTCGAGC 19 61,1 118 NM_006892.3 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
SBF1_2-F GATCCTCAAGCCTCCTGGT 19 59,2 123 NM_002972.3 
SBF1_2-R CCTCCCAGTCCTTCTCTGG 19 59,8 123 NM_002972.3 
SBF1_12-F CGTGGGCTGGTAGAGGAC 18 59,2 115 NM_002972.3 
SBF1_12-R GCACCTCATCGAACAGGTC 19 59,2 115 NM_002972.3 
SBF1_26-F ATGACCATGAGCAGCCTG 18 58,2 105 NM_002972.3 
SBF1_26-R GAAGGGCTCAGACTTGGC 18 58,5 105 NM_002972.3 
SBF1_35-F GTGCAGGGCTGCTGTATG 18 58,9 145 NM_002972.3 
SBF1_35-R CAGCTTACCTCTGCGTCCT 19 58,2 145 NM_002972.3 
SBF1_40-F TGTGGACACAGAGTGCAAGG 20 60,9 123 NM_002972.3 
SBF1_40-R CCAAGGCTCACGTCAAAGA 19 60 123 NM_002972.3 
ITPR1_4-F GGAAAAGCCCTGGGATATCT 20 59,4 127 NM_002222.5 
ITPR1_4-R CGGTTTCTGGCTGTACAACAC 21 60,6 127 NM_002222.5 
ITPR1_6-F GAAAACAGGAAATTGCTGGG 20 59,5 137 NM_002222.5 
ITPR1_6-R TCCAAACCCTGTCTTAGGTGTT 22 59,9 137 NM_002222.5 
ITPR1_10-F AGGAAGAAGCAGCACGTCTT 20 59,2 100 NM_002222.5 
ITPR1_10-R ACCCTACCCTTACCTCCACCT 21 60,1 100 NM_002222.5 
ITPR1_20-F GCTGGATGTCGATCTCATTCT 21 59,3 123 NM_002222.5 
ITPR1_20-R GTGACTTGTTCCTGGGGATC 20 59,4 123 NM_002222.5 
ITPR1_38-F CCTGAGGGAAATGATGACCA 20 60,9 118 NM_002222.5 
ITPR1_38-R AGGTGGGTTTTGAAAGGTCC 20 60,2 118 NM_002222.5 
ITPR1_40-F AGCTCTATGAGCAGGGGTGA 20 60 123 NM_002222.5 
ITPR1_40-R TTCATGGAACACTCGGTCAC 20 59,5 123 NM_002222.5 
ITPR1_44-F ACTGCATAGCCACCCATGA 19 60,1 113 NM_002222.5 
ITPR1_44-R TGCCTTCAGTTCTAACACAAGG 22 59,4 113 NM_002222.5 
ITPR1_48-F GAACAGATAGTCTTTCCCGTGC 22 60,1 136 NM_002222.5 
ITPR1_48-R AGAGGTCTTCAGACCGCAGA 20 60,1 136 NM_002222.5 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
ITPR1_52-F TGGACGGTCCATCATCCT 18 59,8 119 NM_002222.5 
ITPR1_52-R CATTGGGCAGCCTATCTACTTC 22 60,1 119 NM_002222.5 
ITPR1_57-F CCAGGATGAGAGCCATGTC 19 59,1 141 NM_002222.5 
ITPR1_57-R CCTGATCCTTTAATTCCGACAG 22 60 141 NM_002222.5 
SMARCA4_3-F TTCCACATGCTGACCCTG 18 59,1 112 NM_001128849.1 
SMARCA4_3-R ATCCCCATTCCTTTCATCTG 20 58,8 112 NM_001128849.1 
SMARCA4_16-F ATCAAAGGTTTGGAGTGGCT 20 58,6 159 NM_001128849.1 
SMARCA4_16-R AGGCACGATGATGAGGAAG 19 58,8 159 NM_001128849.1 
SMARCA4_30-F CATGACACAGCCAGCAGTG 19 60 131 NM_001128849.1 
SMARCA4_30-R CACGTCCCCAGTGTTGTG 18 59,5 131 NM_001128849.1 
SMARCA4_34-F GAAGACTCCATCGTCTTGCAG 21 60 112 NM_001128849.1 
SMARCA4_34-R CTTCCTCCTCGCCCTCTT 18 59,5 112 NM_001128849.1 
SLC5A2_1-F AGAATGGAGGAGCACACAGAG 21 59,5 105 NM_003041.3 
SLC5A2_1-R CAGGAAATATGCAGCAATGAC 21 58,3 105 NM_003041.3 
SLC5A2_4-F GGTCATCACGATGCCACA 18 60,1 114 NM_003041.3 
SLC5A2_4-R GCACTCACTGAGATCTTGGTGA 22 60,5 114 NM_003041.3 
MARVELD2_2-F ACCAGTGAATGCAGTGTTCTG 21 58,8 137 NM_001038603.2 
MARVELD2_2-R GTCTCCGAGCTGCCTCAT 18 59 137 NM_001038603.2 
MARVELD2_5-F CGCTATAAAGCTGTGTTCCAAG 22 59,1 105 NM_001038603.2 
MARVELD2_5-R GCTCATCACTGCATCCAGC 19 60,5 105 NM_001038603.2 
NAA10_2-F CCAGAGGACCTAATGAACATGC 22 60,9 115 NM_003491.3 
NAA10_2-R TTCAGAAGCTGCCCACCT 18 59,5 115 NM_003491.3 
NAA10_8-F GAGCTGAAAGAGAAGGGCAG 20 59,3 132 NM_003491.3 
NAA10_8-R ACCACTATCCTCGGCAGC 18 58,8 132 NM_003491.3 
CC2D1A_26-F CCAGCAGTACCAGGACATCA 20 59,7 109 NM_017721.4 
CC2D1A_26-R CCACCAGATGCCCATCTC 18 60 109 NM_017721.4 
 
70 
(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
SBF1_3-F ACTGCTGAGCCTTCCCTG 18 59,1 141 NM_002972.3 
SBF1_3-R CTCCCAGAAGGTCAAGCAG 19 58,5 141 NM_002972.3 
SBF1_24-F ACGAGGAGGTGGGGTCTG 18 61,1 118 NM_002972.3 
SBF1_24-R CCAGGTGTGTGGGCAGAG 18 61,4 118 NM_002972.3 
GYG1_2-F CATCTCTGAAACAGCACAGGA 21 59 132 NM_004130.3 
GYG1_2-R GCAACAGGGAGAAGGATGTC 20 59,7 132 NM_004130.3 
GYG1_8-F GGAAGGAACGATGGGAACA 19 60,9 136 NM_004130.3 
GYG1_8-R CAAGGCTTGTGAAGTGGATGT 21 60,2 136 NM_004130.3 
BTK_1-F AGCAGGGAACCAGATAGCAT 20 58,8 121 NM_000061.2 
BTK_1-R AGAGGAAGGACAGTCTGAGCA 21 59,2 121 NM_000061.2 
BTK_3-F CATCTGGTTGCTTAATCCCTCT 22 59,6 158 NM_000061.2 
BTK_3-R GGAATCTGTCTTTCTGGAGGAG 22 59,3 158 NM_000061.2 
BTK_4-F GGTGAAGAGTCCAGTGAAATGG 22 60,9 160 NM_000061.2 
BTK_4-R CTGGGTCCTCGTAGCCTTC 19 59,8 160 NM_000061.2 
BTK_5-F CTGAACACCATTGCTGACTGA 21 59,9 194 NM_000061.2 
BTK_5-R GTTCTTCAGTTGGGGAGAAGAC 22 59,2 194 NM_000061.2 
BTK_6-F TGCTTGAAGTTCACCACTAAGC 22 59,6 149 NM_000061.2 
BTK_6-R GATCCAGAAGCAAGGGTGA 19 58,7 149 NM_000061.2 
BTK_8-F ACCAGTCTCCACAAGTGAGCT 21 59 124 NM_000061.2 
BTK_8-R TGGTAAGTTGCTTTCCTCCAAG 22 60,6 124 NM_000061.2 
BTK_10-F CATGGACAAGCCCTGGAG 18 60,2 126 NM_000061.2 
BTK_10-R AGCAGTTGCTCAGCCTGAC 19 59,3 126 NM_000061.2 
BTK_11-F CCACTTCCTCCTACAGACAGC 21 59 127 NM_000061.2 
BTK_11-R CACTCACCCTGTGGATTTAGC 21 59,6 127 NM_000061.2 
BTK_12-F GTTGACCTTTGTGCCCAAG 19 59,1 103 NM_000061.2 
BTK_12-R TACTGGCTCTGAGGTGTGGA 20 59,4 103 NM_000061.2 
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(cont.) Table S2 – qPCR primers sequence, base pairs, melting temperatures, amplicon base pairs and RefSeq used during design. 
Primer name Primer sequence (5'-3') Primer bp Primer Tm Amplicon bp RefSeq 
BTK_14-F GATCATGGGAAATTGATCCAA 21 59,6 145 NM_000061.2 
BTK_14-R TCATCTTCAGACATGGAGCCT 21 59,8 145 NM_000061.2 
BTK_15-F TGAGAAGCTGGTGCAGTTGT 20 59,6 149 NM_000061.2 
BTK_15-R CCTTGCACATCTCTAGCAGC 20 58,8 149 NM_000061.2 
BTK_16-F GTTTGCACTACAGGCAGCTC 20 58,7 143 NM_000061.2 
BTK_16-R CCTACCCATGTTTCATACTGTGC 23 60,7 143 NM_000061.2 
BTK_17-F ATGTCCTGGATGATGAATACACA 23 59,2 101 NM_000061.2 
BTK_17-R AGATTTGCTGCTGAACTTGCT 21 59,3 101 NM_000061.2 
BTK_19-F ATGTCATGGATGAAGAATCCTG 22 58,9 116 NM_000061.2 
BTK_19-R GCTCCAGGGCTCCTAAGC 18 60,1 116 NM_000061.2 
MCCC2_1-F CCTCTACCAGGTAGGCTGAGC 21 60,4 102 NM_022132.4 
MCCC2_1-R GACAAGAGAGCAGCAGTTGTTG 22 60,2 102 NM_022132.4 
MCCC2_10-F TGCAGGTCACCATTGAACC 19 60,5 137 NM_022132.4 
MCCC2_10-R GCTGGTCATAAAGCTCACAGTTC 23 60,3 137 NM_022132.4 
MCCC2_17-F TTCCTTGGCATTTCTGCAC 19 59,8 141 NM_022132.4 
MCCC2_17-R ACTGAGACCCAAGACCAGTCTG 22 60,7 141 NM_022132.4 
ABCA3_5-F GCTTGAAGATTCAGTCGGAAA 21 59,4 133 NM_001089.2 
ABCA3_5-R CTGTGAGAAGGGATGTAGGCA 21 60,3 133 NM_001089.2 
ABCA3_12-F CATCCAGTGGCGAGACCT 18 59,8 121 NM_001089.2 
ABCA3_12-R CTCCATGTACCAGGTCACCAG 21 60,4 121 NM_001089.2 
ABCA3_22-F TCTTCAGGGCTTCTGTGGAG 20 60,5 131 NM_001089.2 
ABCA3_22-R AGTGGCTGGAGAGTGGTACG 20 60,3 131 NM_001089.2 
ABCA3_32-F GAGGACTCCAGTGCTGAGC 19 58,6 116 NM_001089.2 
ABCA3_32-R CATGCCTTGGTGCTCATCT 19 59,8 116 NM_001089.2 
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ANNEX III - Method Validation – Results Comparison 
Table S3- Results comparison between qPCR and previous results for methodology validation 
Sample Gene Fragment MLPA Result aCGH Result Other Tests qPCR Result 
Prediction Value 
MLPA aCGH Other 
A1 MECP2 MECP2_2 Normal - - Normal 0 - - 
A1 MECP2 MECP2_3 Normal - - Normal 0 - - 
A1 MECP2 MECP2_4A Normal - - Normal 0 - - 
A1 MECP2 MECP2_4C Normal - - Normal 0 - - 
A4 MECP2 MECP2_2 Normal Normal - Normal 0 0 - 
A4 MECP2 MECP2_3 
c.27-
?_704+?del; 
Heterozygous 
deletion of 
exon 3 and part 
of exon 4 
arr 
Xq28(153,297,503-
153,314,668)x1; 
Heterozygous 
deletion of exon 3 
- Heterozygous Deletion 0 0 - 
A4 MECP2 MECP2_4A 
c.27-
?_704+?del; 
Heterozygous 
deletion of 
exon 3 and part 
of exon 4 
Normal - Heterozygous Deletion 0 1 - 
A4 MECP2 MECP2_4C Normal Normal - Normal 0 0 - 
A5 MECP2 MECP2_2 
c.1-
?_c.1461+?dup; 
Heterozygous 
duplication 
- - Heterozygous Duplication 0 - - 
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(cont.) Table S3- Results comparison between qPCR and previous results for methodology validation. 
Sample Gene Fragment MLPA Result aCGH Result Other Tests qPCR Result 
Prediction Value 
MLPA aCGH Other 
A5 MECP2 MECP2_3 
c.1-
?_c.1461+?dup; 
Heterozygous 
duplication 
- - Heterozygous Duplication 0 - - 
A5 MECP2 MECP2_4A 
c.1-
?_c.1461+?dup; 
Heterozygous 
duplication 
- - Heterozygous Duplication 0 - - 
A5 MECP2 MECP2_4C 
c.1-
?_c.1461+?dup; 
Heterozygous 
duplication 
- - Heterozygous Duplication 0 - - 
A10 NF1 NF1_13 
Hemizygous 
deletion in DMD 
gene 
- - Normal 0 - - 
A10 NF1 NF1_14 
Hemizygous 
deletion in DMD 
gene 
- - Normal 0 - - 
A10 NF1 NF1_58 
Hemizygous 
deletion in DMD 
gene 
- - Normal 0 - - 
A11 NF1 NF1_13 
c.1-
?_8457+?del; 
Heterozygous 
deletion 
- - Heterozygous Deletion 0 - - 
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(cont.) Table S3- Results comparison between qPCR and previous results for methodology validation. 
Sample Gene Fragment MLPA Result 
aCGH 
Result 
Other Tests qPCR Result 
Prediction Value 
MLPA aCGH Other 
A11 NF1 NF1_14 
c.1-
?_8457+?del; 
Heterozygous 
deletion 
- - 
Heterozygous 
Deletion 
0 - - 
A11 NF1 NF1_58 
c.1-
?_8457+?del; 
Heterozygous 
deletion 
- - 
Heterozygous 
Deletion 
0 - - 
A12 NF1 NF1_13 Normal - 
Duplication of exon 13 
detected by NGS and 
qPCR at another lab 
Normal 0 - -1 
A12 NF1 NF1_14 Normal - Normal Normal 0 - 0 
A12 NF1 NF1_58 Normal - Normal Normal 0 - 0 
A10 PARK2 PARK2_4 
Hemizygous 
deletion in DMD 
gene 
- - Normal 0 - - 
A10 PARK2 PARK2_7 
Hemizygous 
deletion in DMD 
gene 
- - Normal 0 - - 
A10 PARK2 PARK2_12 
Hemizygous 
deletion in DMD 
gene 
- - Normal 0 - - 
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(cont.) Table S3- Results comparison between qPCR and previous results for methodology validation. 
Sample Gene Fragment MLPA Result 
aCGH 
Result 
Other Tests qPCR Result 
Prediction Value 
MLPA aCGH Other 
A13 PARK2 PARK2_4 
c.172-?_534+?del; 
c.172-?_734+?del; 
Compound 
heterozygous 
deletion of exons 3 
to 4 and 3 to 6 
- 
Sequencing failure of 
exons 3 and 4 
(Sanger) 
Homozygous/
Compound 
Heterozygous 
Deletion 
0 - 0 
A13 PARK2 PARK2_7 Normal - Normal Normal 0 - 0 
A13 PARK2 PARK2_12 Normal - Normal Normal 0 - 0 
A14 PARK2 PARK2_4 
c.413-?_871+?del; 
Heterozygous 
deletion of exons 4 
to 7 
- - 
Heterozygous 
Deletion 
0 - - 
A14 PARK2 PARK2_7 
c.413-?_871+?del; 
Heterozygous 
deletion of exons 4 
to 7 
- - 
Heterozygous 
Deletion 
0 - - 
A14 PARK2 PARK2_12 Normal - - Normal 0 - - 
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ANNEX IV – Primers Validation 
Table S4 - Primers efficiency, R
2
 and PCR characteristics for the tested genes. 
Primer Efficiency R
2
 Primer Volume (µL) Melting Temperature (⁰C) 
ABCA3_5 0,85 0,996 0,4 99 
ABCA3_12 0,95 0,996 0,4 99 
ABCA3_22 0,92 0,993 0,4 99 
ABCA3_32 0,83 0,992 0,4 99 
ADAMTS2_3 1,10 0,988 0,4 95 
ADAMTS2_13 1,12 0,997 0,4 95 
ADAMTS2_22 1,01 0,996 0,4 95 
ASXL3_2 0,87 0,957 0,4 95 
ASXL3_3 0,82 0,994 0,9 95 
ASXL3_8 0,89 0,990 0,4 95 
ASXL3_11 0,84 0,983 0,4 95 
ASXL3_12 0,85 0,997 0,4 95 
BCKDHA_2 0,91 0,995 0,9 95 
BCKDHA_3 0,93 0,987 0,4 95 
BCKDHA_4 0,86 0,992 0,4 95 
BCKDHA_6 0,90 0,994 0,4 95 
BTK_1 0,94 0,974 0,4 95 
BTK_3 0,86 0,993 0,4 95 
BTK_4 0,79 0,978 1,0 95 
BTK_5 0,87 0,991 1,0 95 
BTK_6 0,81 0,981 1,0 95 
BTK_8 0,81 0,977 0,6 95 
BTK_10 0,89 0,991 0,4 95 
BTK_11 0,83 0,979 0,8 95 
BTK_12 0,82 0,983 0,8 95 
BTK_14 0,82 0,983 0,4 95 
BTK_15 0,92 0,993 1,0 95 
BTK_16 0,80 0,991 0,4 95 
BTK_17 0,89 0,988 0,8 95 
BTK_19 0,96 0,996 0,8 95 
CC2D1A_2 0,91 0,994 0,4 95 
CC2D1A_14 0,85 0,987 0,4 95 
CC2D1A_16 1,00 0,978 0,4 95 
CC2D1A_28 1,01 0,992 0,4 99 
CD96_2 0,91 0,996 0,4 95 
CD96_15 0,87 0,995 0,4 95 
COL6A1_8 1,04 0,996 0,4 99 
COL6A1_9 0,93 0,995 0,3 99 
COL6A1_14 1,00 0,989 0,4 99 
COL6A1_33 0,90 0,992 0,4 99 
COL6A2_i1 0,96 0,981 0,4 95 
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(cont.) Table S4 - Primers efficiency, R2 and PCR characteristics for the tested genes. 
Primer Efficiency R
2
 Primer Volume (µL) Melting Temperature (⁰C) 
COL6A2_5 0,83 0,981 0,4 95 
COL6A2_10 0,80 0,990 0,4 95 
COL6A2_11 0,87 0,991 0,4 95 
COL6A2_26 1,06 0,957 0,4 95 
DNMT3B_3 1,00 0,996 0,6 95 
DNMT3B_11 1,01 0,997 0,6 95 
DNMT3B_22 0,81 0,992 0,4 95 
ERCC3_2 1,02 0,991 0,4 95 
ERCC3_8 0,88 0,990 0,4 95 
ERCC3_14 0,85 0,992 0,4 95 
ESCO2_2 0,86 0,968 0,4 95 
ESCO2_7 0,85 0,983 0,4 95 
ESCO2_11 0,88 0,938 0,4 95 
FANCC_1 1,10 0,972 0,4 99 
FANCC_2 0,83 0,973 0,4 95 
FANCC_4 0,85 0,986 0,8 95 
FANCC_14 0,86 0,991 0,8 95 
FBN2_2 0,98 0,989 0,4 95 
FBN2_23 0,97 0,998 0,4 95 
FBN2_65 0,88 0,995 0,4 95 
GYG1_2 1,04 0,992 0,6 99 
GYG1_8 0,88 0,992 0,4 99 
IL7R_3 0,87 0,973 0,4 95 
IL7R_8 0,90 0,974 0,4 95 
ITPR1_4 1,03 0,994 0,4 95 
ITPR1_6 0,98 0,993 0,4 95 
ITPR1_10 0,86 0,989 0,4 95 
ITPR1_20 0,98 0,994 0,4 95 
ITPR1_38 0,97 0,992 0,4 95 
ITPR1_40 0,94 0,985 0,4 95 
ITPR1_44 0,94 0,984 0,4 95 
ITPR1_48 0,82 0,992 0,6 95 
ITPR1_52 0,90 0,981 0,4 95 
ITPR1_57 0,96 0,992 0,4 95 
MARVELD2_2 1,02 0,997 0,4 95 
MARVELD2_5 0,95 0,997 0,4 95 
MCCC2_1 0,95 0,993 0,4 99 
MCCC2_10 0,88 0,993 0,4 95 
MCCC2_17 0,87 0,990 0,4 95 
MGME1_2 0,83 0,947 0,4 95 
MGME1_3 0,95 0,996 0,6 95 
MGME1_5 0,83 0,979 0,4 95 
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(cont.) Table S4 - Primers efficiency, R2 and PCR characteristics for the tested genes. 
Primer Efficiency R
2
 Primer Volume (µL) Melting Temperature (⁰C) 
MMACHC_1 0,94 0,990 0,6 95 
MMACHC_2 1,01 0,993 0,4 95 
MMACHC_4 0,86 0,996 0,4 95 
MVK_3 0,93 0,980 0,4 95 
MVK_4 0,73 0,965 0,9 95 
MVK_6 0,98 0,972 0,4 95 
MYO15A_3 1,16 0,989 0,4 95 
MYO15A_16 0,93 0,991 0,4 95 
MYO15A_30 0,91 0,991 0,4 95 
MYO15A_45 0,89 0,985 0,4 95 
MYO15A_66 0,89 0,995 0,4 95 
NAA10_2 1,04 0,983 0,4 95 
NAA10_8 1,05 0,989 0,4 95 
PEX1_6 0,90 0,988 0,6 95 
PEX1_9 0,90 0,990 0,4 95 
PEX1_12 1,01 0,994 0,4 95 
PEX1_14 0,91 0,986 0,4 95 
PEX1_24 0,99 0,996 0,4 95 
SAG_2 0,86 0,993 0,4 95 
SAG_16 1,00 0,989 0,4 95 
SBF1_3 1,06 0,993 0,4 95 
SBF1_12 1,02 0,992 0,4 95 
SBF1_26 0,98 0,985 0,2 99 
SBF1_35 1,11 0,987 0,45 95 
SBF1_40 0,88 0,983 0,4 95 
SLC5A1_2 0,93 0,992 0,4 95 
SLC5A1_7 0,93 0,995 0,4 95 
SLC5A1_i14 0,82 0,997 0,4 95 
SLC5A1_15 0,92 0,964 0,4 95 
SLC5A2_1 1,00 0,992 0,6 95 
SLC5A2_4 0,86 0,994 0,6 99 
SLC5A2_14 0,90 0,995 0,4 95 
SMARCA4_3 0,93 0,969 0,4 95 
SMARCA4_16 0,97 0,994 0,4 95 
SMARCA4_30 0,93 0,990 0,4 95 
SMARCA4_34 0,84 0,995 0,6 99 
THPO_3 0,98 0,983 0,6 95 
THPO_4 0,80 0,978 0,4 95 
THPO_6 0,80 0,949 0,4 95 
VCP_2 1,00 1,000 0,6 95 
VCP_8 0,80 0,992 0,4 95 
VCP_16 0,82 0,992 0,4 95 
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ANNEX V – Relative Quantitation Results 
Table S5 - Relative quantitation results for the 
samples used as normal controls. 
Control Samples 
Primer Sample Copy Number 
ABCA3_5 POOL 1,01 
ABCA3_12 POOL 1,02 
ABCA3_22 POOL 0,97 
ABCA3_32 POOL 1,01 
ADAMTS2_13 POOL 0,93 
ADAMTS2_22 POOL 1,10 
ADAMTS2_3 POOL 1,09 
ASXL3_11 POOL 0,99 
ASXL3_12 POOL 0,88 
ASXL3_2 POOL 0,90 
ASXL3_3 POOL 0,93 
ASXL3_8 POOL 1,00 
BCKDHA_2 POOL 0,97 
BCKDHA_3 POOL 0,95 
BCKDHA_4 POOL 0,99 
BCKDHA_6 POOL 1,04 
BTK_1 POOL 1,02 
BTK_10 POOL 0,99 
BTK_11 POOL 0,99 
BTK_12 POOL 0,91 
BTK_14 POOL 1,05 
BTK_15 POOL 1,02 
BTK_16 POOL 0,96 
BTK_17 POOL 1,06 
BTK_19 POOL 1,02 
BTK_3 POOL 1,06 
BTK_4 POOL 1,07 
BTK_5 POOL 0,99 
BTK_6 POOL 1,06 
BTK_8 POOL 1,01 
CC2D1A_14 POOL 0,98 
CC2D1A_16 POOL 1,02 
CC2D1A_2 POOL 0,96 
CC2D1A_28 POOL 1,03 
CD96_15 POOL 1,03 
CD96_2 POOL 0,95 
COL6A1_14 POOL 1,07 
COL6A1_14 POOL 0,98 
 
Control Samples 
Primer Sample Copy Number 
COL6A1_33 POOL 1,02 
COL6A1_8 POOL 1,02 
COL6A1_9 POOL 1,14 
COL6A2_10 A8 1,00 
COL6A2_11 A17 0,89 
COL6A2_26 POOL 0,90 
COL6A2_5 A8 1,12 
COL6A2_i1 A17 1,09 
COL6A3_1 POOL 1,01 
COL6A3_16 POOL 1,05 
COL6A3_43 POOL 0,92 
DNMT3B_11 POOL 0,97 
DNMT3B_22 POOL 0,96 
DNMT3B_3 POOL 0,99 
ERCC3_14 POOL 1,01 
ERCC3_2 POOL 0,99 
ERCC3_8 POOL 0,99 
ESCO2_11 POOL 1,01 
ESCO2_2 POOL 0,99 
ESCO2_7 POOL 1,04 
FANCC_1 POOL 1,10 
FANCC_14 POOL 1,07 
FANCC_2 POOL 1,02 
FANCC_4 POOL 0,97 
FBN2_2 POOL 1,08 
FBN2_23 POOL 1,09 
FBN2_65 POOL 0,98 
GYG1_2 POOL 1,05 
GYG1_8 POOL 1,07 
IL7R_3 POOL 1,07 
IL7R_3 POOL 0,96 
IL7R_8 POOL 1,10 
IL7R_8 POOL 1,05 
ITPR1_10 POOL 1,09 
ITPR1_20 POOL 0,96 
ITPR1_38 POOL 0,92 
ITPR1_4 POOL 0,95 
ITPR1_40 POOL 1,00 
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(cont.) Table S5 - Relative quantitation results for 
the samples used as normal controls. 
Control Samples 
Primer Sample Copy Number 
ITPR1_44 POOL 1,06 
ITPR1_48 POOL 0,97 
ITPR1_52 POOL 1,13 
ITPR1_57 POOL 1,07 
ITPR1_6 POOL 0,92 
MARVELD2_2 POOL 0,98 
MARVELD2_5 POOL 1,05 
MCCC2_10 POOL 0,98 
MCCC2_17 POOL 0,99 
MCCC2_2 POOL 1,07 
MGME1_2 POOL 1,08 
MGME1_3 POOL 1,13 
MGME1_5 POOL 1,09 
MMACHC_1 POOL 1,09 
MMACHC_2 POOL 1,07 
MMACHC_4 POOL 1,07 
MVK_3 POOL 0,95 
MVK_4 POOL 1,00 
MVK_6 POOL 1,07 
MYO15A_16 POOL 0,96 
MYO15A_3 POOL 1,00 
MYO15A_30 POOL 1,11 
MYO15A_45 POOL 0,94 
MYO15A_66 POOL 0,95 
NAA10_2 POOL 1,00 
NAA10_8 POOL 1,02 
PEX1_12 POOL 1,05 
PEX1_14 POOL 1,00 
PEX1_24 POOL 1,05 
 
Control Samples 
Primer Sample Copy Number 
PEX1_6 POOL 0,98 
PEX1_9 POOL 1,03 
SAG_16 POOL 1,01 
SAG_2 POOL 0,99 
SBF1_12 POOL 1,00 
SBF1_26 POOL 1,03 
SBF1_3 POOL 1,06 
SBF1_35 POOL 1,11 
SBF1_40 POOL 1,01 
SLC5A1_15 POOL 1,06 
SLC5A1_2 POOL 1,05 
SLC5A1_7 POOL 1,03 
SLC5A1_i14 POOL 1,03 
SLC5A2_1 POOL 1,01 
SLC5A2_14 POOL 0,99 
SLC5A2_4 POOL 1,08 
SMARCA4_16 POOL 1,11 
SMARCA4_3 POOL 1,05 
SMARCA4_30 POOL 0,99 
SMARCA4_34 POOL 1,02 
THPO_3 POOL 1,02 
THPO_3 CT_aCGH 1,08 
THPO_4 POOL 1,07 
THPO_4 CT_aCGH 1,02 
THPO_6 POOL 1,00 
THPO_6 CT_aCGH 1,15 
VCP_16 POOL 0,91 
VCP_2 POOL 0,98 
VCP_8 POOL 0,95 
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Table S6 - Relative quantitation results for the test 
samples scored as normal. 
Normal Samples 
Primer Sample Copy Number 
ABCA3_5 A80 1,01 
ABCA3_12 A80 0,93 
ABCA3_22 A80 1,00 
ADAMTS2_13 A56 0,95 
ADAMTS2_22 A56 0,91 
ADAMTS2_3 A56 1,08 
ASXL3_11 A49 1,09 
ASXL3_11 A48 0,99 
ASXL3_12 A49 1,03 
ASXL3_12 A48 0,94 
ASXL3_2 A49 1,19 
ASXL3_2 A48 0,99 
ASXL3_3 A49 1,15 
ASXL3_3 A48 1,03 
ASXL3_8 A49 1,10 
ASXL3_8 A48 1,12 
BCKDHA_4 A53 0,85 
BCKDHA_6 A53 0,85 
BTK_1 A68 0,98 
BTK_10 A68 0,93 
BTK_11 A68 0,93 
BTK_12 A68 0,99 
BTK_14 A68 1,04 
BTK_15 A68 0,94 
BTK_16 A68 0,95 
BTK_17 A68 1,06 
BTK_19 A68 1,06 
BTK_3 A68 0,99 
BTK_4 A68 0,88 
BTK_5 A68 0,92 
BTK_6 A68 0,96 
BTK_8 A68 0,97 
CC2D1A_14 A57 1,05 
CC2D1A_16 A57 1,15 
CC2D1A_2 A57 1,09 
CC2D1A_28 A57 1,08 
CD96_15 A62 0,98 
CD96_2 A62 1,09 
COL6A1_33 A20 0,85 
COL6A1_8 A20 0,97 
 
Normal Samples 
Primer Sample Copy Number 
COL6A1_9 A20 1,01 
COL6A2_i1 A17 0,81 
COL6A2_10 A20 0,96 
COL6A2_11 A20 1,11 
COL6A2_26 A20 0,87 
COL6A2_5 A20 0,89 
COL6A3_1 A20 0,91 
COL6A3_16 A20 1,09 
COL6A3_43 A20 1,04 
DNMT3B_11 A65 1,06 
DNMT3B_22 A65 0,99 
DNMT3B_3 A65 0,97 
ERCC3_14 A58 0,92 
ERCC3_2 A58 0,90 
ERCC3_8 A58 0,96 
ESCO2_11 A34 0,93 
ESCO2_2 A34 1,12 
ESCO2_7 A34 0,97 
FANCC_1 A16 0,91 
FANCC_14 A16 0,94 
FANCC_2 A16 1,12 
FANCC_4 A16 1,14 
FBN2_2 A59 0,93 
FBN2_23 A59 1,06 
FBN2_65 A59 0,97 
GYG1_2 A76 0,98 
GYG1_8 A76 0,90 
IL7R_3 A66 1,11 
IL7R_3 A32 0,97 
IL7R_8 A66 1,07 
IL7R_8 A32 0,90 
ITPR1_10 A64 0,97 
ITPR1_20 A64 0,93 
ITPR1_38 A64 0,99 
ITPR1_4 A64 1,06 
ITPR1_40 A64 0,93 
ITPR1_44 A64 1,00 
ITPR1_48 A64 0,90 
ITPR1_52 A64 0,90 
ITPR1_57 A64 0,88 
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(cont.) Table S6 - Relative quantitation results for 
the test samples scored as normal. 
Normal Samples 
Primer Sample Copy Number 
ITPR1_6 A64 0,93 
MARVELD2_2 A75 1,13 
MARVELD2_5 A75 1,16 
MCCC2_10 A79 0,98 
MCCC2_17 A79 0,90 
MCCC2_2 A79 0,96 
MGME1_2 A33 0,88 
MGME1_3 A33 0,94 
MGME1_5 A33 1,11 
MMACHC_1 A54 0,93 
MMACHC_2 A54 0,88 
MMACHC_4 A54 1,02 
MVK_3 A50 1,07 
MVK_4 A50 1,14 
MVK_6 A50 0,91 
MYO15A_16 A35 1,04 
MYO15A_3 A35 1,08 
MYO15A_30 A35 1,08 
MYO15A_45 A35 1,08 
MYO15A_66 A35 1,08 
NAA10_2 A78 1,17 
NAA10_8 A78 0,99 
PEX1_12 A50 0,89 
PEX1_14 A50 0,95 
PEX1_24 A50 0,89 
PEX1_6 A50 0,93 
PEX1_9 A50 0,92 
 
Normal Samples 
Primer Sample Copy Number 
SAG_16 A55 1,09 
SAG_2 A55 1,00 
SBF1_12 A63 0,94 
SBF1_26 A63 0,97 
SBF1_3 A63 1,10 
SBF1_35 A63 0,95 
SBF1_40 A63 0,93 
SLC5A1_15 A52 0,85 
SLC5A1_2 A52 0,91 
SLC5A1_7 A52 1,14 
SLC5A1_i14 A52 0,98 
SLC5A2_1 A60 1,06 
SLC5A2_14 A60 0,93 
SLC5A2_4 A60 0,91 
SMARCA4_16 A77 0,93 
SMARCA4_3 A77 1,13 
SMARCA4_30 A77 0,94 
SMARCA4_34 A77 1,07 
THPO_3 A67 1,02 
THPO_3 A25 0,92 
THPO_4 A67 0,89 
THPO_4 A25 0,91 
THPO_6 A67 0,93 
THPO_6 A25 0,97 
VCP_16 A61 0,92 
VCP_2 A61 0,92 
VCP_8 A61 0,91 
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Table S7 - Relative quantitation results for the test samples scored as deleted and duplicated. 
Deleted Samples Duplicated Samples 
Primer Sample Copy Number Primer Sample Copy Number 
COL6A1_14 A20 0,63 BTK_1 POOL_F 2,13 
COL6A1_14 A20 0,52 BTK_3 POOL_F 2,01 
ABCA3_32 A80 0,47 BTK_5 POOL_F 1,99 
ABCA3_32 A80 0,50 BTK_6 POOL_F 2,06 
BCKDHA_2 A53 0,01 BTK_8 POOL_F 1,96 
BCKDHA_3 A53 0,03 BTK_10 POOL_F 2,12 
 BTK_11 POOL_F 2,36 
BTK_12 POOL_F 2,23 
BTK_14 POOL_F 2,17 
BTK_15 POOL_F 1,96 
BTK_16 POOL_F 2,02 
BTK_17 POOL_F 2,01 
BTK_19 POOL_F 1,58 
NAA10_2 POOL_F 1,28 
NAA10_8 POOL_F 1,43 
 
